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SHORT SUMMARY 
During the last years transdermal drug delivery has gained increasing interest 
due to the high acceptance of patients. However the major problem of drug delivery via 
the cutaneous route are the barrier properties of the skin which are located in the stratum 
corneum. To study the potential of polymeric biodegradable nanocarriers on drug 
delivery to and through the skin  the well known biodegradable copolymer poly(D,L-
lactide-co-glycolide) (PLGA 50:50) was used as main component of the carrier system. 
As model drug  flufenamic acid, an antiinflamatory drug, was incorporated. Nanoparticles 
in the size range of 200 to 400 nm were prepared by means of a solvent extraction 
technique. In vitro skin transport experiments using Franz diffusion cell systems and the 
Saarbrücken model showed an enhancement effect for encapsulated flufenamic acid 
independent of particle size. Surprisingly, also the presence of drug-free nanoparticles in 
a preparation (hydrogel) with flufenamic acid in solution has also increased the 
permeated amount of drug. As mechanism of action an acidic nano-environment around 
the particles could be identified by confocal laser scanning microscopy and permeation 
experiments using buffered and non-buffered preparations. Other studies have shown 
that nanoparticles were able to penetrate into the hair follicles when massage was used. 
These results underscore the potential of polymeric biodegradable nanoparticles as 
carriers for transdermal drug delivery. Especially, the acidic pH of the nano-environment 
of the particles might be an advantage to develop special formulations designed for 
acidic drugs or might be used to re-establish the physiological acidic pH on the skin 
surface. 
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KURZZUSAMMENFASSUNG  
Infolge der hohen Akzeptanz bei Patienten hat die transdermale Applikation von 
Arzneistoffen mittels Trägersystemen in den letzten Jahren zunehmend an Bedeutung 
gewonnen. Für die kutane Arzneistoffinvasion stellen jedoch die Barriereeigenschaften 
der Haut, welche im Stratum corneum lokalisiert sind, ein großes Problem dar. Um das 
Potential polymerer, bioabbaubarer und nano-partikulärer Trägersysteme auf die 
Arzneistoffinvasion in und durch die Haut zu untersuchen, wurde das schon ausführlich 
charakterisierte sowie bioabbaubare Copolymer Poly-(D,L-lactide-co-glycolide) (PLGA 
50:50) als Trägermaterial eingesetzt. Als Modellarzneistoff wurde Flufenaminsäure, eine 
antiinflamatorisch wirksame Substanz, in die Nanopartikel inkoorperiert. Unter 
Verwendung der „Lösungsmittel Extraktions Technik“ wurden Partikel im Größenbereich 
von 200 bis 400 nm hergestellt. Durch in vitro Experimente mit Franz-Diffusionszellen 
und dem Saarbruecker-Penetrationsmodell konnte gezeigt werden, dass, unabhängig 
von der Partikelgröße, der Arzneistofftransport verkapselter Flufenaminsäure in bzw. 
durch die Haut erhöht war. Überraschender Weise konnte bei Zugabe arzneistofffreier 
Nanopartikel in eine Zubereitung (Hydro-Gel) welche Flufenaminsäure in gelöster Form 
enthielt ebenfalls eine erhöhte Arzneistoffpermeation beobachtet werden. Mittels 
Konfokaler Mikroskopie und Permeationsexperimenten wurde als 
Wirkungsmechanismus, sowohl für gepufferte als auch für ungepufferte Präparationen, 
ein saurer pH-Wert im Nanometerbereich um die Partikel herum nachgewiesen. Des 
weiteren konnte gezeigt werden, daß Nanopartikel unter Anwendung einer Massage in 
Haarfollikel penetrieren. Die Ergebnisse unterstreichen das Potential polymerer, 
bioabbaubarer Nanopartikel als Trägersysteme für die transdermale Anwendung. 
Insbesondere der saure pH-Wert im Nanometerbereich um die Partikel könnte Vorteile 
für die Entwicklung spezieller Formulierungen für saure Arzneistoffe bieten. Weiterhin 
wäre auch eine mögliche Applikation zur Wiederherstellung des physiologischen, leicht 
sauren pH-Wertes der Hautoberfläche im Fall pathophysiologischer Veränderungen 
denkbar. 
  
 
 
 
 
 
 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
Sections of this chapter: 
- Have been submitted for publication as part of the book chapter entitled 
“Models for skin absorption and skin toxicity testing”, Preclinical 
Biopharmaceutics - in situ, in vitro, and in silico tools for drug absorption 
studies, Springer (in preparation) 
- Will be submitted as part of the review article entitled “Nanoparticles – present 
and future as drug delivery systems to the skin”, European Journal of 
Pharmaceutics and Biopharmaceutics (in preparation). 
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1.1. THE DERMAL BARRIER 
The skin, in Latin called cutis, is considered the largest organ of the body, 
accounting more than 10% of the body mass and having an average surface of 
approximately 2 m2. This organ enables the body to interact most intimately and 
dynamically with the environment. The functions of the skin are considered essential for 
the survival of the human beings in a relatively aggressive environment, providing a 
multifunctional interface between the body and the surrounding media. These functions 
have been classified as protective, homeostatic, or sensorial. The first two mentioned are 
mainly function of its barrier properties, allowing the survival of humans among changes 
in environmental temperature, relative humidity, dangerous substances such as 
chemicals, bacteria, allergens, radiation, etc. To maintain its characteristics, this organ is 
in a continual renewing process [1]. Due to its barrier properties, the skin membrane is 
equally capable at limiting the molecular transport from and into the body. Overcoming 
this barrier function will be the purpose of transdermal drug delivery. 
In order to understand the biopharmaceutical effects of dermatological 
formulations, it is necessary to know the anatomy, physiology and chemical composition 
of the skin.  
Anatomically, the skin consists on 4 basic layers: the stratum corneum (nonviable 
epidermis), viable epidermis, dermis and subcutaneous tissues (Figure 1). In addition to 
these structures, there are also several associated appendages: hair follicles, sweat 
glands, apocrine glands, and nails.  
The subcutaneous tissues, the innermost layer, is characterized by a fibrous 
connective structure, which is composed mainly by elastic fibres and fat. This layer acts 
as insulator, shock absorber, and reserve depot of calories and supplier of nutrients for 
the more superficial skin layers. On its domain are found the base of the hair follicles, the 
secretory portion of the sweat glands, the cutaneous nerves as well as networks of 
lymph and blood vessels. 
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Figure 1: Structure of the human skin1  
 
The dermis is a fibrous layer that supports and strengthens the epidermis. Its 
thickness varies from 2-3 mm. It consists of a matrix of loose connective tissue 
composed by collagen, a fibrous protein, embedded in a semigel matrix, which contains 
water, ions and mucopolysaccharides. This matrix helps to hold the cells and allows the 
oxygen and nutrients to diffuse to the epidermal cells. This layer contains an extensive 
blood vessel and nervous network, as well as hair follicles, sebum and sweat glands. 
The most adjacent layer of the dermis, called papillary layer, provides the nutritional 
support to the viable epidermis. The papillary layer plays no only a nutritional function but 
also a role in the temperature, pressure and pain regulation. In addition, it contains a 
sparse cell population: fibroblasts, responsible for the connective tissue synthesis; mast 
cells, which are involved in the immune and inflammatory responses; and melanocytes, 
involved in the production of melanin. 
                                                 
 
1 Modified from the source  http://www.agen.ufl.edu/~chyn/age2062/lect/lect_19/lect_19.htm, 14.02.2007 
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The viable epidermis consists of several cell strata varying in the differentiation 
level. From the bottom, the stratum basale is composed of two keratinocyte types, one 
that acts as stem cells having a proliferation capacity, and the second one which serves 
as anchor to the basement membrane. It contains as well: Merkel cells, Langerhans cells 
and melanocytes.  
During the differentiation process the epidermal layers (stratum spinosum, 
granulosum, lucidum and corneum) are converted to corneocytes. Herein cellular 
changes includes the extrusion of lamellar bodies, loss of the nucleus and an increase in 
the keratin amount until the stratum corneum is formed [1, 2].  
The stratum corneum (SC), the outermost layer of the epidermis, also called 
non viable epidermis, has an approximately thickness of 10 – 20 µm that can vary from 
one body site to the other. It consists, in a given cross-section, of 15 – 25 flattened, 
stacked, hexagonal, and cornified cells (corneocytes, also called horny cells) anchored in 
a mortar of highly organized intercellular lipids. This structure has been described as 
brick and mortar model (Figure 2) and is considered the rate controlling barrier in the 
transdermal absorption of substances. Each corneocyte is approximately 40 µm in 
diameter and 0.5 µm thick, and it is composed mainly of insoluble bundled keratins 
(approx. 70%) and lipid (~20%) located in the cell envelope. The intercellular matrix 
consists of lipids and desmosomes for the corneocyte cohesion [1]. The lipids of this area 
are distinctive in many respects: (i) they provide the only continuous phase (diffusion 
pathway) from the skin surface to the base of the SC; (ii) its composition (mainly 
ceramides, free fatty acids and cholesterol) is unique among biological membranes and 
particularly noteworthy is the absence of phospholipids; (iii) despite this deficit of 
phospholipids, polar bilayer-forming lipids, the SC lipids exist as multilamellar sheets; 
and (iv) the predominantly saturated, long-chain hydrocarbon tails facilitate a highly 
ordered, interdigitated configuration (Figure 2).  The staggered corneocyte arrangement 
in a lipid matrix is suggested to provide a highly tortuous lipoidal diffusion pathway 
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rendering the membrane 1000 times less permeable to water relative to other biological 
membranes Due to the continuous phase, the intercellular lipid layer is considered the 
most important transdermal absorption pathway for small substances [3]. The turnover of 
the complete SC layer occurs once every 2 – 3 weeks [1]. 
 
Figure 2: Schematic representation of the “brick and mortar” model of the stratum corneum,  
lipid bilayer organisation and possible pathways 2 
 
The SC by its composition and structure is considered to act as the main barrier 
for the exchange of substances between the body and the environment. And therefore 
became the real challenge on drug delivery into and through the skin. Moreover, this 
anatomical barrier is accompanied by the intracutaneous metabolism, a high drainage 
rate due to blood and lymph capillary present in the dermis and a peripheral immune 
system [4]. 
 
                                                 
 
2 Reprinted from International Journal of Pharmaceutics, Vol. 131, Moghimi HR, Williams AC, Barry BW, A 
lamellar matrix model for stratum corneum intercellular lipids II. Effect of geometry of the stratum corneum 
on permeation of model drugs 5-fluorouracil and oestradiol, p119, Copyright 1996, with permission from 
Elsevier. 
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1.2. TRANSDERMAL DRUG DELIVERY 
During the last years, developments in transdermal drug delivery have been 
incremented focusing mainly on overcoming problems associated with the skin barrier 
properties. Nevertheless, the transdermal delivery offers several advantages: the skin 
represents a relatively large and readily accessible surface area for absorption, the 
application is a non-invasive procedure that allows a continuous intervention, and it is 
possible to cease the absorption preventing overdose or undesirable effects. Compared 
with the traditional oral administration route, transdermal delivery shows additional 
advantages: it minimize the first-pass metabolism, it avoids drug degradation under the 
extreme acidity of the stomach, it prevents erratic delivery due to food interactions, and it 
provides more controlled delivery. Among its major disadvantages are: not all 
compounds are suitable for transport across the skin, there are different permeation rates 
depending on age, race, site of application and individuals, and also skin diseases can 
influence it [5, 6].  
The goal of the transdermal administration of drugs is not to achieve a bolus-type 
drug input; rather, it is usually designed to offer a slow, sustained release of drug over 
long periods of time. Current transdermal delivery systems, as transdermal occlusive 
patches, are capable to deliver drugs in cases that oral administration is limited by poor 
bioavailability, side effects associated with high peak plasma concentrations or poor 
compliance due to the need of frequent administration [3, 7].  
The criteria that merit consideration in transdermal delivery of drugs are: the 
nature of the barrier (discussed in the previous section), the balance between 
physicochemical properties of the membrane and the drug, and the technologies 
available to facilitate the transdermal transport.  
Under normal conditions, there are three pathways postulated for the absorption 
of substances through the SC: transcellular, intercellular (paracellular) (Figure 2) and 
transappendageal [5]. The predominant route of transdermal penetration of the majority 
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of the applied drugs is through intercellular spaces; therefore, the transdermal pathway is 
much longer than the normal stratum corneum thickness (~20 µm) which was estimated 
as long as 500 µm. If the transcellular pathway is predominant, the diffusion involves 
several partitioning steps into the lipo- and hydrophilic domains of the corneocytes and 
the lipid layers before reaching the viable epidermis [8]. The transdermal absorption 
process requires drug characteristics or an appropriate carrier which should be able to 
deliver the drug to the desired skin deepness to reach topical or systemic effects. 
In general the barrier limitations imposes that the drug chosen for transdermal 
delivery should be pharmacologically potent and has physicochemical characteristics 
which allow it to cross the main barrier, the stratum corneum. Among these requirements 
are: the drug must possess both lipoidal and aqueous solubility, which promote its 
permeation through the domains of the stratum corneum, i.e. and appropriate partition 
coefficient (KO/W ~ 1-3) to have an optimum absorption ; the drug mobility must be high, 
i.e. molecular weight and volume must be appropriate to facilitate its diffusion through the 
lipid bilayer. The permeation through the skin will also depend on the ionization degree of 
the drug at physiological and formulation pH, influencing as well its solubility and partition 
behaviour [3, 4, 8, 9]. 
A good transdermal delivery system must not only provide an adequate drug 
release from the formulation, but also allow considerable  amounts of drug to overcome 
the skin barrier, ensure a non-irritancy of the skin, and also ensure that the drug will not 
be inactivated on the skin’s  surface or during the permeation process [10]. 
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1.2.1.  Strategies to overcome the epidermal barrier 
Since several years, researchers have been working on the development of new 
strategies to improve the delivery of drugs through the skin. These could be separated in 
physical and chemical methods. 
 
Physical enhancement methods  
♦ Iontophoresis, which involves the use of low current via an electrode in 
contact with the skin, inducing the drug delivery promotion through ion 
repulsion, decrease on the resistance of the skin and electroosmosis in case 
of large molecules. 
♦ Electroporation that uses the application of high voltage impulses during a 
very short time to create temporary pores on the skin, the driving force of the 
drug permeation is the ion repulsion or the electroosmosis.  
♦ Sonophoresis uses low frequency ultrasonic energy to disrupt the lipid 
packing in the SC creating aqueous pores which improve the drug delivery.  
♦ Local thermal treatments [4, 11]. 
♦ Mechanical perforation of the SC by high-velocity particles (ballistic) [11]. 
♦ Micro-needles array inducing the temporary loose of the barrier properties 
until the layer is recovered by the normal turnover cycle, as well as local 
thermal treatments have been used to deliver drugs [12].  
General Introduction 
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Drug delivery systems 
♦ Lipidic flexible particles as liposomes, niosomes, ethosomes and 
transferosomes. 
♦ Solid lipid nanoparticles and nanostructured lipid carriers  
♦ Solid polymeric nanoparticles, of biodegradable and non-biodegradable 
characteristics [11] 
 
Chemical enhancement methods  
♦ Increasing the hydration state of the SC by a high water content in the 
formulation or by occlusion (which prevents the trans-epidermal water loss 
from the tissue), some examples of this effect are given by patches and 
ointments, but tissue over-hydration is not a general rule for penetration 
enhancement;  
♦ enhancers which disrupt the lipid organization in the SC such as azone, 
terpenes, fatty acids, dimethylsulphoxide (DMSO) and alcohols; 
♦ compounds able to alter the protein organization in the SC, such as DMSO or 
urea;  
♦ compounds which increase the solubility of the drug within the SC, e.g. 
Transcutol® P.  
The enhancement effect can also act indirectly, for example: 
♦ modifying the thermodynamic activity of the drug in the formulation at the 
moment of the application, e.g. ethanol; 
♦ solubilizing the drug in the donor, in case of poor soluble substances, e.g. 
surfactants. 
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The main disadvantage of the chemical penetration enhancers is that most of 
them induce irritation or sensitation, cause damage and reduce the barrier function for a 
longer time. These conditions are not desirable in the process of transdermal drug 
administration [11, 13] 
 
1.3.  SELECTED DRUG CARRIER SYSTEMS FOR DERMAL DELIVERY 
 
1.3.1.  Solid nanocarriers in transdermal drug delivery 
During the last decades, the study of inorganic and colloidal particles such as 
nanocapsules, nanospheres, nanostructured lipid carrier, etc. has been focused as 
dermal/transdermal drug delivery carriers. Some of them will be addressed in detail in the 
following section.  
In general, solid colloidal nano-carriers systems have been extensively studied as 
drug delivery systems (DDS), mostly for oral and parenteral applications, and have 
shown to be one of the most promising strategies to achieve site-specific drug delivery 
[14]. To be considered as potential human drug delivery systems requires that the 
material has to be biocompatible, preferentially biodegradable, or at least should be able 
to be excreted [15]. This my be the reason why only a limited number of biodegradable 
polymeric nanoparticles [9, 16-20], solid lipid nanoparticles (SLN) and nanostructured 
lipid carriers (NLC) [21-30] have been studied with respect to their potential for drug 
systemic and topical administration. Nanoparticles can be used to deliver a wide variety 
of substances as hydrophilic or hydrophobic drugs, proteins, vaccines, biological 
macromolecules, etc., and they can be formulated for targeted delivery, e.g. to the brain, 
lungs, lymphatic system, or made for long term systemic circulation [16]. 
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1.3.1.1 Lipid nanocarriers 
Both, SLN and NLC, are composed of physiological and biodegradable lipids, 
which possess a low cytotoxicity and also low systemic toxicity [31].  SLN consist of pure 
solid lipid while NLC are made of a solid matrix entrapping liquid lipid compartment [25]. 
These carriers have been the most extensively studied for drug and cosmetic dermal 
applications. 
There are two main preparation methods described for SLN, the high pressure 
homogenization methods, which can be performed under hot or cold conditions 
depending on the drug stability, and the microemulsion technique. 
SLN posses some advantages when compared with liposomes (also lipid carriers 
but without a solid structure) and emulsions, e.g. the protection against chemical 
degradation of the drug and the modulating capacity of the active compound release. 
The main disadvantage of SLN is that during storage the drug entrapped is expulsed due 
to a change in the lipid conformation to a lower energy crystal state, a transformation 
from polymorphic to perfect crystals, which allow no guest molecules in the structure. To 
overcome this problem NLC were developed. In these nano-carriers, solid and liquid lipid 
are mixed in such a combination that the particle solidifies upon cooling but does not re-
crystallize, remaining in amorphous state. This allows the drug to be accommodated in 
the particle for a longer time and will increase the drug loading capacity of the systems 
[24]. 
Several authors have studied the potential of SLN and NLC as topical delivery 
systems. Examples of the use of lipid solid nanocarriers are: Santos Maia et al (2000)  
have shown that the incorporation of prednicarbate into SLN increase the amount of drug 
which penetrated the human skin layers compared with a commercially available cream 
[27]; on the other hand, Wissing and Müller (2002) incorporating the sunscreen 
oxybenzone into SLN, reported a decrease of the SC penetration, characteristic desired 
when sunscreens are used [32].  
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The potential of these carriers are variable and must be studied specifically for 
the drug and delivery system. 
 
1.3.1.2 Polymeric nanocarriers 
Not as extensively as SLN the potential of polymeric nanocarriers have been 
studied for skin drug delivery. 
Polymeric nanoparticles are particles of less than 1000 nm in diameter that can 
be prepared from natural or synthetic polymers. Natural polymers, such as protein and 
polysaccharides, have been not widely used since they vary in purity, and often require 
preparation processes which can lead to drug degradation. The most widely used 
polymers are synthetic polymers as polyalkylcyanoacrylates, poly(lactic acid), 
poly(glycolic acid) or their copolymers, poly(lactide-co-glycolide), etc. The last mentioned 
polymers have a very well known biocompatibility and resorbability through natural 
pathways, and their degradation and drug release rate can be regulated according to the 
polymer composition (monomers proportions and linkages)  [16, 33].  
Poly(D,L-lactide-co-glycolide) (PLGA) have been extensively studied for different 
therapeutic applications such as sustained drug, vaccine, and gene delivery [34-36]. 
PLGA microparticles were described as vehicles for topical drug delivery, providing a 
reservoir system for release into the skin [19, 36]. Other polymeric nanoparticles 
examples have been: poly(ε-caprolactone) NP, used by Alvarez-Román (2004) et al to 
increase the availability of octyl methoxycinnamate within the SC [9];  and chitosan NP, 
used by Cui and Mumper (2001) for vaccine delivery to the viable epidermis [17]. 
Despite of the apparent advantages compared with other DDS, polymeric 
nanoparticles appear rather unexplored for drug delivery to the skin. 
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1.3.2.  Nanocarrier – skin interaction mechanism 
Following the topical application of a dermatological formulation the absorption of 
the active compound could follow the transcellular, intercellular (paracellular) and 
transappendageal pathway through the epidermal barrier.  
The mechanism of interaction of the nanoparticulated carrier systems and the 
skin and also the transport pathways within the membrane of the drug and/or the carrier, 
are required to establish the possibility of using such systems to optimize the drug 
transport process [9]. It has been described that SLN, due to its particle size, are able to 
ensure a high adhesion to the SC enhancing the amount of drug which penetrates into 
the viable skin. Furthermore, for SLN particles between 200 and 400 nm an occlusive 
effect has been described on artificial membranes [30], and reducing the trans-epidermal 
water loss and increasing the penetration of a occlusion sensitive drug into the skin 
layers [29, 37].  
In another hand, in vivo studies indicated that NLC have been able to increase 
the anti-inflamatory effect of indomethacin on the time, correlated well with an increased 
permanence of the drug in the SC layers studied using tape stripping method [23].  
The role of the hair follicles in the penetration process is often neglected based 
on the fact that the orifices of the hair follicles occupy only approximately 0.1% of the 
total skin surface area. However it is not considered that the hair follicles is an 
invagination of the epidermis extended deep into the dermis, increasing the absorption 
area below the skin surface [38, 39].  
In the case of polymeric carriers, Rolland et al have demonstrated hair follicle 
targeting using 5 µm PLGA-adapalen-loaded microparticles [38], as well as de Jalon et al 
have shown PLGA-microparticles penetration into porcine skin [36]. In other studies, 
copolymer nanoparticles have been shown by Shim et al to deliver monoxidil through the 
skin in a size dependent form when hairy rats where used [20]. Using polystyrene 
nanoparticles of 20 and 200 nm in diameter and porcine ear skin, Alvarez-Román et al 
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have demonstrated that particles accumulate in the follicular opening and that smaller 
particles favour this localization [40]. Bigger particles of the same polymer (0.75 – 6 µm) 
were tested by Lademann’s group showing in vitro and in vivo size dependent particle 
penetration that was independent of the hair type (terminal vs. vellus hairs). A massage 
increased the penetration into the hair follicle [41]. Finally, the same group have 
extensively studied the follicle penetration of particles using human skin and titanium 
dioxide microparticles which were found to reach only the outer layers of the SC as well 
as deep into the hair follicles. They stated out that particle penetration was dependent on 
the “activity” of the hair follicle, i.e. hair growth and sebum production will influence the 
particle penetration process [42-45]. As described before, follicular penetration of 
nanoparticles (see figure 3) appear to be a promising mechanism for drug delivery. 
 
 
Figure 3: Size dependence of hair follicle particle penetration 3 
 
The hair follicle delivery has several pharmacokinetic advantages as a reduction 
or bypass of the tortuous pathway of the transepidermal absorption, decrease of the drug 
systemic toxicity when the follicle act as long term delivery reservoir and increasing 
                                                 
 
3 Reprinted from Roberts M.S. et al, Dermatological and transdermal formulations, page 175, figure 35, 
Marcel Dekker , Inc., 2002, with permission from Taylor & Francis (UK). 
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additionally the therapeutic index of some drugs as well as reducing the applied dose or 
frequency of administration. Micro- as well as nanoparticles have been demonstrated to 
reach deep into the hair follicles, where the barrier posses only a few layers of 
differentiated corneocytes and can be considered highly permeable, and additionally the 
hair follicles can act as long-term reservoir, beneficial condition when transdermal 
delivery is intended. 
Techniques as confocal laser scanning microscopy (CLSM) offer the possibility of 
visualizing the distribution of fluorescent probes in a skin sample by optical sectioning 
without previous cryofixation or embedding of the tissue, and it is considered as a 
valuable method for reporting the extent of penetration of molecules into the skin and for 
identifying the transport pathways [9]. Multi-photon fluorescence imaging can also be 
applied as technique for determinations in vivo tissue absorption/accumulation of 
dermatological and cosmetical preparations, such as interaction of nanoparticulated 
systems with the skin [46, 47].  
 
1.3.3.   Nanocarrier toxicology 
Nanocarriers are present in different dermatological and cosmetic formulations. 
The most commonly used carriers are liposomes; solid poorly soluble materials as 
titanium dioxide and zinc oxide; polymer particles and SLN.  
The small size of the carriers give them an increased ratio surface to total atoms 
or molecules exposed to the interaction with cellular systems, increasing its biological 
activity. This large activity can either positive (e.g. antioxidant, carrier capacity for 
therapeutics, penetration of cellular barriers for drug delivery) or negative (e.g. toxicity, 
induction of oxidative stress or of cellular disfunction), or a mixture of both. However, in 
strong contrast to the efforts to increasing its positive properties for improving the human 
health are the limited attempts to evaluate the potentially undesirable effects of 
nanoparticles when administered for medical or cosmetical purposes [48].  
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Some of the studies undertaken to evaluate the toxicological potential of 
dermatologically applied nanoparticles have reported the following results: 
♦ Titanium dioxide nano- and microparticles have been studied by 
Lademann et al who report that micro-sized particles get through the 
human SC and into the hair follicles [44]; on other study, carried by 
Menzel et al, using commercially available sunscreen creams and pig skin 
has reported the penetration of nanoparticles (approximately 15 nm in 
diameter) in the SC and into the underlying stratum granulosum through 
the intercellular space [49]. Gamer et al studied the penetration of zinc 
oxide by tape-stripping method on porcine skin and found that 
approximately 100% of the applied amount remain in the uppermost 
layers of the SC, only a few samples showing the presence of particles in 
the deeper layers [50]. 
♦ PLGA microparticles (1-10 µm in diameter) have been studied by de 
Jalón et al using pig skin and were found to penetrate into the viable 
epidermis [36]. 
♦ Solid lipid nanoparticles have shown lower toxicity than poly(lactide-co-
glycolide) or polyalkylcyanoacrylate nanoparticles when administered 
intravenously [31], but there are no studies performed when topically 
applied. 
 
Limited literature or qualitative information about penetration and effect of 
nanoparticles during the skin transport is available, only in the case of liposomes, zinc 
oxide and titanium dioxide nanoparticles toxicological information is available. In general,  
only a few conclusions can be made about the toxicological potential of nanocarriers: 
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♦ Penetration of the skin layers is size dependent. 
♦ Different type of particles have different behaviour with respect to the 
dermal membrane, and it is not possible to predict either its permeation or 
toxicological behaviour. 
♦ Parts or materials which can dissolve or leach from the particles can 
possibly penetrate the skin. 
♦ There are other studies, using particles not intended for dermatological 
use that have shown that particles can be phagocytized by macrophages 
or Langerhans cells, and this process can induce a sensitation response. 
♦ There is no evidence that particle applied to the skin can penetrate and 
enter the systemic circulation when applied to normal skin [51]. 
The available data suggest that dematologically applied nanoparticles have a  low 
human risk, but is necessary more information about the real effects under in vivo 
conditions. 
 
1.4. FLUFENAMIC ACID AS A MODEL DRUG 
Flufenamic acid (FFA), a non-steroidal anti-inflammatory drug, is known as 2-[[3-
(trifluoromethyl) phenyl] amino] benzoic acid (see figure 4). This drug is a weak acid 
soluble in organic solvents as methanol, ethanol, chloroform, and acetone, and it has a 
very low solubility in water at 22 °C 0.0067 mg/ml which can vary depending on the pH 
with a dissociation constant (pKa) of 3.9. Its solubility is increased by non-ionic 
surfactants, and by urea and sodium citrate. Flufenamic acid 1-octanol/water partition 
coefficient (log P) have been estimated by Dunn with a value of 4.88, and Terada et al 
have determined it experimentally obtaining a log P equal to 5.62 [52, 53]. 
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Figure 4: Chemical structure of flufenamic acid 
 
From this drug exists several described modifications which differ on its crystal 
properties. The present work will be referred to FFA modification II that has a melting 
point of 128°C [52]. 
Human pharmacokinetics: FFA is intestinally absorbed in a pH dependent form, 
and in extent of 100% of the administered dose, from which 51% is eliminated as drug 
and its metabolites by renal way. The active undergoes metabolic transformations to FFA 
glucuronide, 5- and/or 4’-hydroxy FFA and its respective glucuronides. Due to its 
hydrophobicity it highly binds to proteins (have been studied using bovine and human 
serum albumin, BSA and HSA respectively), and FFA have shown a site specific binding 
when HSA is used, that is characteristic for drugs which contain aromatic carboxylic acid, 
as ibuprofen and flurbiprofen [52]. Skin pharmacokinetic behaviour has not been 
described, however, Wagner et al  have shown that in the stratum corneum the 
concentration of drug increases with the incubation time, and have a good linear 
correlation among the in vitro test systems, e.g. Franz-diffusion cell system and 
Saarbrücken model, and the in vivo drug penetrated amount. In the same way the drug 
concentration rises in the deeper skin layer, but only in vitro information is available [54]. 
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1.5. IN VITRO METHODS FOR TRANSDERMAL DRUG DELIVERY 
ASSESSMENT  
 
1.5.1.  In vitro permeation studies 
The studies of in vitro skin permeation are the most common experimental set-
ups for the control of dermatological formulations. It has been carried out using a wide 
variety of experimental protocols dependent on the research group, the substances in 
study and the purpose of the substance or formulation applied to the skin. 
The in vitro methods involve the diffusion measurement of substances through 
the skin, bioengineered, various skin layers, or artificial membranes to a receptor fluid 
assembled in a diffusion cell, which can be static or flow-through (see figure 5). In Franz 
diffusion cell systems (FD-C), the formulation or substance in study is placed in the donor 
compartment, separated from the receptor compartment by a membrane, e.g. full 
thickness skin, epidermis or SC sheets, splitted skin from human or animal origin or 
bioengineered materials (keratinocyte cultures). The receptor compartment is usually a 
buffer solution, with a composition as close as possible to physiological conditions, 
normally pH 7.4. If the solubility of the substance is low, substances as ethanol, proteins, 
cyclodextrins or some surfactants can be added [55]. The sampling is performed either in 
a continuous form or at pre-determined time intervals. The system is maintained at 
constant temperature under conditions which simulate the skin surface temperature 
(32°C). 
 
Figure 5: Schematic representation of Franz diffusion test systems: Horizontal static (left) 
and flow through (right) diffusion cell 4 
                                                 
 
4 Reprinted from Walters K.A.  and Roberts M.S., Dermatological and transdermal formulations, page 200, 
Marcel Dekker , Inc., 2002 
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The dosage regime of the formulation in made under infinite (> 10 µl/cm2 or 
mg/cm2) or finite dose (≤10 µl/cm2 or mg/cm2) conditions and the donor compartment can 
be under occlusion or opened to the environment. In the first case, the occlusion of the 
system leads normally to an excessive hydration of the skin, and the second allows the 
evaporation of volatile substances.  
Constant stirring of the system ensure the diffusion of the drug by 
homogenization of the receptor. The sink conditions are maintained along the 
experimental time under the following conditions: (i) in the receptor compartment only 
10% of the saturation concentration is reached; (ii) the membrane is unaffected during 
the experimental time [56]. 
 
1.5.2.  In vitro penetration studies 
The Saarbrücken model (SB-M) was introduced in skin research by Loth and co-
workers [57-61] and has been described in detail by Wagner et al [54]. Briefly, the skin is 
put onto a filter paper soaked with Ringer solution and placed into the cavity of a Teflon 
block. The drug preparation is filled into a cavity of a Teflon punch of 2 mm in depth, 
which is applied to the skin surface and a weight of 0.5 kg is placed on top of the punch 
for 2 min, to improve the contact between the skin and the drug preparation. After this 
time, the punch is fixed on its place and the gap between the two Teflon parts is sealed 
with Plastibase® to avoid the skin water loss. See a representation of the system on 
figure 6. The whole system is transferred into a plastic box and placed into a water bath, 
or into a forced air circulation oven, at (32 ±1) °C [54]. 
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Figure 6: Schematic representation of the Saarbrücken penetration system. 
If compared with FD-C, SB-M avoids the non-physiological hydration and 
changes of the skin due to the absence of liquid as receptor medium.  This system, 
coupled to segmentation techniques, such as tape stripping or cyosectioning, allows the 
measurement of penetration profiles of the drug with respect to the depth of the tissue. 
Under infinite dose conditions, a excessive amount of drug is applied to the skin, 
ensuring a reproducible way of application It is expected that the SC reach saturation 
and the effect of rubbing due to application procedure is avoided. Under finite dose 
conditions, only a limited amount of preparation is applied to the skin surface, and it is 
possible to observe the influence of other factors such as evaporation of excipients. 
This model is suitable to study semisolid and liquid formulation (using porous 
holders), as well as patches. The experiments are carried out with different incubation 
time points. Consequently, the drug distribution in the skin layers or the formation of 
depots can be observed. At the end of the incubation time the preparation is removed 
from the skin surface, the thickness of the skin is measured and the tissue is segmented 
under standardized procedure. 
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1.6. CALCULATION OF PARAMETERS TO DESCRIBE TRANSDERMAL 
ABSORPTION 
For practical reasons only the processes considered on the development of this 
thesis are mathematically described. Schematically, in vitro and in vivo processes are 
presented in the figure 7. 
 
 
Figure 7: Diagrammatic representation of the processed involved on in vitro and in vivo 
percutaneous absorption 5 [62] 
                                                 
 
5 Adapted from Roberts and Anissimov, 2005 [62]  
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As shown in figure 7, under in vitro conditions, the volume (V) and the 
concentration of the donor compartment are considered to be constant over the 
experimental time, even though the receptor volume (Vr) and its clearance (Clr) are 
limited. On the other hand, under in vivo conditions, the concentration on the dermal 
tissue is conditioned to the clearance due to capillary network (ClB) and to the 
elimination/distribution from this fluid. 
The data obtained from the in vitro permeation experiments can be plotted and 
several parameters can be calculated from them. Examples of the typical obtained 
curves with the different dosage regimes are shown in figure 8. 
 
 
Figure 8: Cumulative permeation patterns following finite- and infinite-dosing regimes 6 
  
 
                                                 
 
6 from Walters K.A.  and Roberts M.S., Dermatological and transdermal formulations, page 209, figure 4, 
Marcel Dekker , Inc., 2002 
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1.6.1.  In vitro permeation studies using infinite dose regime 
Most of the in vitro studies using infinite dose conditions are carried out assuming 
that:  
♦ the concentration in the donor compartment (Cv), i.e. in the formulation 
applied, does not change considerably (change < 10%) during the 
experimental time; 
♦ the drug concentration in the receptor compartment does not exceed 10% 
of the saturation concentration on the receptor media, i.e. the sink 
conditions, in the receptor compartment, are maintained during the 
experimental time;  
♦ and the characteristics of the membrane does not change during the 
experimental time. 
If the transport through the SC is the rate limiting process, the steady-state 
approximation of the amount of solute permeated (Q) with a apparent permeation 
constant (Papp) and a lag-time (tlag) when the concentration of the donor (Cv) is applied to 
a determined area (A) during a exposure time (t) can be represented though the 
equation 1. 
If the transport through SC is the rate limiting process, after a certain lag-time 
steady-state conditions will be achieved. Assuming a  homogeneous membrane, the 
drug permeation can be described by diffusion and Fick’s first law can be applied. 
)( lagvapp ttACPQ −=  
Equation 1: Steady-state permeated amount. 
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Rearranging equation 1 leads to:  
ss
lag
vapp JttA
QCP =−= )(  
 
Equation 2: Flux under steady-state conditions 
 
With the flux at steady-state (J), which is represented by the slope of the linear 
part of a diagram of the permeated amount of drug per area versus time (figure 8) .  
Then, the apparent permeability constant (Papp) represents the transport speed of 
the drug through the membrane, and can be calculated using the Jss and Cv. 
 
1.6.2.  In vitro penetration experiments using infinite dose regime 
Using the Saarbrücken model two types of data handling are possible:  
1. Concentration – skin depth profile:  
Plotting drug concentration in the different skin layers (mass of drug per thickness 
of the layer per area) versus skin depth (see figure 10). In this case, the formation of 
depots in the different layers can be observed.  
 
Figure 9: Example of penetration profiles of drug into the stratum corneum and deeper skin 
layers  respect to the depth, using the same formulation (infinite dose regime) at different 
incubation time. 
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For detailed information concerning the calculation steps see Wagner et al (2000) 
[54] 
Furthermore, area under the penetration curve can be calculated using the 
trapezoidal rule (see equation 3). Which may serve as surrogate for the bioavalability of 
the substance in each layer. 
∑
=
−− −+=−
n
i
iiiin ttCCtAUC
1
11 ))((2
1)0(  
Equation 3: Area under the curve trapezoidal rule – General equation 
 
2. The calculation of penetrated amount of drug in each layer, i.e. SC or deep skin 
layers, respect to the incubation time (see figure 9). In this case the influence of 
incubation time, drug concentration and excipients can be observed, as well as, 
saturation of the stratum corneum or the influence of different skin donors and 
anatomical regions. 
 
Figure 10: Example of cumulative amount of drug into the stratum corneum and deeper skin 
layers using different formulations (infinite dose regime) according to the incubation time 
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1.7. MICRODIALYSIS AS IN VIVO DERMAL PHARMACOKINETIC TOOL 
Born in neurosciences, the microdialysis as sampling technique have been used 
since several years to monitor the drug absorption and disposition from the extracellular 
space different organs, fluids and tissues, becoming used as technique in human 
research during the late 80’s. 
It consists of a microdialysis probe, a thin hollow tube made of a semi-permeable 
membrane, normally of around 200 – 500 µm in diameter, which is implanted into the 
skin and perfused with a receiver solution (perfusate) that  recovers the unbound 
permeant from the local area (dialysate) which is collected and analysed. In principle, the 
dialysis driving force of the molecular moving is the diffusion down the concentration 
gradient existing between two compartments separated by a semi-permeable membrane 
(see figure 11), that for skin in vivo conditions these compartments are represented for 
the dermal or subcutaneous extracellular fluid and the artificial physiological solution in 
the microdialysis probe lumen. In essence, the principle of the microdialysis is to create 
an “artificial blood vessel” where the diffusion of compounds flows on the direction of 
lowest concentration [63-66].  
 
Figure 11: Microdialysis principle 7 
                                                 
 
7 adapted from Elmquist and Sawchuk, 1997 [66] 
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The material of the microdialysis membrane must be biocompatible and inert, 
respect to the substance in study and to the tissue components. The molecular weight 
cut-off 8 must be large enough to allow the free diffusion of the solute, but small enough 
to assure the exclusion of proteins and other macromolecules. The most commonly used 
materials have been: cellulose, cellulose-acetate, polycarbonate, polyarylethersulphone, 
etc. 
For pharmacokinetic studies, different probe designs such as linear or concentric 
style were used.  
Fick’s second Law that considers the concentration gradient and diffusion rate of 
the substance from the medium and the surface area of the membrane mathematically 
describes diffusion microdialysis processes. One of the most important parameters to be 
considered is the flow rate of the perfusate (solution that comes into the probe), which is 
normally in the range of 0.1 – 5 µl/min, inversely related to the amount of drug recovered 
in the dialysate (solution that comes out of the probe). Other factors that strongly 
influence the drug recovery from the surrounding medium are: the lipophilicity of the 
substance, i.e. as more hydrophobic or protein bound substance as less recovered using 
an aqueous perfusate media, and the molecular weight and volume of the substance that 
will limit the pass through the dialysis membrane according to its molecular cut-off. To 
improve the recovery of lipophilic drugs strategies as addition of solvents (e.g., 
polyethylene glycol, cyclodextrins, proteins, or lipids) to the perfusate have been used 
[63, 65, 67]. 
The relative recovery (RR) of the probe, essential for data interpretation, is 
normally calculated using the retro-dialysis method, which assumes that the net transport 
                                                 
 
8 Usually defined as the molecular weight in Daltons at which 80% of the molecules are prevented from 
passing through the membrane. 
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through the microdialysis membrane from the perfusate to the surrounding tissues 
equals the net transport from the tissues into the perfusate. The relative recovery is 
calculates using the equation 4 [67]:  
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
perfusate
dialysateperfusate
C
CC
RR  
Equation 4:  Relative recovery of a microdialysis probe using retrodialysis method.  
 
Among the techniques to determine cutaneous availability, such as tape stripping, 
biopsies or imaging procedures, microdialysis has shown to be promising having several 
advantages for the assessment of in-vivo drug pharmacokinetic profiles. The minimally 
invasive procedures ensures minor reversible trauma, allowing long term sampling under 
physiological conditions in awake individuals, that the individual itself is its own control, 
and the good temporal resolution of tissue concentration, make this technique, compared 
with the other above mentioned, require a lower number of volunteers. The obtained 
samples, due to the relatively low molecular cut-off of the membrane, are protein free 
allowing sample analysis without any further purification step and avoiding the enzymatic 
degradation of the sample. As the substance in study can be included on the perfusate, 
in situ metabolism can be acquired. Nevertheless, the small sample size is a 
disadvantage since it requires very sensitive analytical methods [56, 67, 68] 
An increasing number of studies using microdialysis of a wide range of drugs in 
animal and human subjects were performed, supporting the potential of this technique for 
bioavailability and bioequivalence studies. Some examples of studies in-vitro as well as 
in-vivo, involving different delivery systems and species are: iontophoretic drug delivery 
in rats by Mathy et al [69];  oral delivery and skin pharmacokinetics by Bielecka-Grzela 
and Klimowicz [70]; determination of salicylic compounds on rat skin by Simonsen et al 
[71], and in human skin by Leveque et al [72]; anaesthetic extended release products in 
human skin by Kopacz et al [73]; among others. 
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OBJECTIVES 
During the last years, the interest over the nanoparticles as drug delivery carrier 
system has increased due to its potential of controlled release, targeting, and stability 
advantages over other carrier systems. Several strategies, including physical and 
chemical methods, have been used to improve the delivery of drugs through the skin. 
During the last decades, the study of the potential of the nanotechnology for transdermal 
drug delivery have been mainly focused on the study of the use of solid lipid 
nanoparticles and nanostructured lipid carriers and only a few studies have been centred 
on the use of biodegradable polymeric nanoparticles. 
The aim of this doctoral thesis is to study the potential of the biodegradable 
polymeric nanoparticles, made of  poly(D,L-lactide-co-glycolide) (PLGA) , as transdermal 
delivery system. Following this general purpose, the specific objectives are:  
♦ To study the effect of PLGA nanoparticles on the skin permeation using 
flufenamic acid as model drug 
♦ To study the mechanism how PLGA nanoparticles enhance/retard the 
permeation of flufenamic acid through the skin 
♦ To study the effect of PLGA nanoparticles on the skin absorption of 
flufenamic acid in vivo 
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CHAPTER 2: PLGA NANOPARTICLES AS TRANSDERMAL CARRIER 
 
 
 
 
 
 
The content of this chapter have been published in the research article entitled 
“Influence of nanoencapsulation on human skin transport of flufenamic acid” (Javiana 
Luengo, Barbara Weiss, Marc Schneider, Alexander Ehlers, Frank Stracke, Karsten 
Koenig, Karl-Heinz Kostka, Claus-Michael Lehr, and Ulrich F. Schaefer), Skin 
Pharmacology and Physiology, 19(4):  190 – 197. Published by S Karger AG, Basel. 
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2.1. ABSTRACT 
The effect of the inclusion of flufenamic acid in PLGA nanoparticles on the 
transport of flufenamic acid into excised human skin was investigated. Penetration and 
permeation data were acquired using two different in vitro test systems: the 
Saarbruecken penetration model (SB-M), where the skin acts as its own receptor 
medium, and the Franz diffusion cell (FD-C), where the receptor medium is a buffer 
solution. For the stratum corneum no differences were found between nanoencapsulated 
and free drug. Drug accumulation in the deeper skin layers and drug transport across 
human epidermis was slightly delayed for the nanoencapsulated drug compared to the 
free drug after shorter incubation times (< 12 h). In contrast, after longer incubation times 
(> 12 h) the nanoencapsulated drug showed a statistically significant enhanced transport 
and accumulation (P<0.05). Additionally, nanoencapsulated flufenamic acid was 
visualized by multiphoton fluorescence microscopy. Particles homogeneously distributed 
on the skin surface and within the dermatoglyphs were found, but no nanoparticles within 
or between the corneocytes were detected. 
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2.2. INTRODUCTION  
Due to its special structure, the skin provides the main barrier between the body 
and the environment, at the same time it limits the drug delivery along this route [1, 6, 8, 
74, 75]. Many strategies have been employed to improve the dermal and transdermal 
delivery of drugs, e.g. increasing the effective concentration of the drug in the vehicle, 
improving the partitioning between the formulation and the skin, the use of chemical 
penetration enhancers and different physical enhancement methods [6, 76]. 
Furthermore, carrier systems like liposomes, microparticles or nanoparticles (NP) [11, 77, 
78] have been explored. For microparticles, some targeting to the hair follicles has been 
shown by Toll et al. [41], using polystyrene microspheres in a range of 0.75–6 µm, and 
Lademann et al. [79], using titanium dioxide particles in a range of 0.1–0.3 µm also 
resulting in an enhanced delivery to the deeper skin layers. Studies on solid lipid NP [27, 
29, 30] also showed increased transdermal drug delivery induced by their occlusive 
effects. Alvarez-Román et al. [40] reported preferential accumulation of non-
biodegradable drug-free polymeric NP in the hair follicle opening of pig skin. In addition, 
the same authors reported an increased level within the stratum corneum of the pig ear 
of the highly lipophilic sun-protecting agent, octylmethoxycinnamate, when 
nanoencapsulated in the biodegradable polymer poly(ε-caprolactone) [9]. 
Some of the most widely used polymers in the NP formulation are poly(lactic 
acid), poly(glycolic acid), and their co-polymer, poly(lactide- co -glycolide) (PLGA), which 
are known for their good biocompatibility and resorbability through natural pathways [33]. 
In oral and parenteral applications, solid biodegradable polymeric NP based on PLGA 
have shown their advantage over liposomes by their increased stability [16, 80, 81], but 
in the field of dermal delivery their potential appears to be rather unexplored. 
The objective on this chapter was to investigate the influence of 
nanoencapsulation on the permeation and penetration of the lipophilic model drug 
flufenamic acid (FFA) into skin using PLGA as carrier polymer. In order to monitor drug 
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penetration, the Saarbrücken model [54] (SB-M) was used in which the skin itself acts as 
a receptor compartment. A tape stripping technique followed by cryosectioning of the 
deeper skin layers allows the quantification of the penetrated drug amount. Drug release 
from the formulation and drug permeation through the epidermis were studied using the 
static Franz diffusion cell (FD-C) technique. 
Due to the size differences between the hair follicles of pig skin and of human 
skin [82], which may play an important role in the results, we decided to use excised 
human skin from abdominal plastic surgery instead of pig skin. As polymer, PLGA was 
chosen in view of its excellent biocompatibility and the availability of various methods to 
prepare drug-loaded NP from this polymer. To verify the presence and to visualize the 
distribution of the applied NP on the skin, multiphoton fluorescence imaging was used. 
This technique allows to excite the natural fluorescence of the FFA in non-polar 
surroundings (λ max = 420 nm) by a two-photon absorption process. Two-photon 
excitation induced with femtosecond near infrared laser pulses offers the possibility of 
high-resolution 3-dimensional imaging of the skin [83]. 
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2.3. MATERIALS AND METHODS 
2.3.1.  Materials  
Natrosol® 250 M (Aqualon, Hercules Inc., DE, USA), Flufenamic acid, 
modification II (Kali-Chemie Pharma, Hannover, D), Poly(D,L-lactide-co-glycolide) 
(50:50) with a molecular weight of 40000 to 75000 Da (Sigma Chemical Co., St. Louis, 
MO, USA), Polyvinyl alcohol (PVA) Mowiol® 4-88 (Kuraray Specialities Europe GmbH, 
Frankfurt, D), Ringer solution, McIlvaine citric acid phosphate buffer (pH 2.2), Sodium 
hydroxide solution (0.05 M) (all components from Merck, Darmstadt, D), Plastibase® 
(Heiden GmbH, Muenchen, D), Methanol Chromasolv® (Sigma-Aldrich GmbH, Seelze, 
D), Tesa Film Kristall-klar 19 mm (Tesa AG, Hamburg, D), Ethyl acetate (Fluka Chemie 
GmbH, Bucks, Switzerland), Cellulose membrane MWCO 12000 – 14000 Da (Medicell 
International Ltd., London, LX, USA) were used as obtained from the suppliers.  
 
2.3.2.  Equipment 
HPLC System: ChromeleonTM Version 6,5 SP2, build 968; P580 Pump; ASI-100 
automated sample injector; STH 585 Column oven; UVD 170S Detector (Dionex Softro 
GmbH, Germering, D); Franz diffusion cell type 6G-01-00-15 (Perme Gear, Riegelsville, 
PA, USA); Cryomicrotome HR Mark II, model 1978 (Slee, Mainz, D); Centrifuge Sigma 
3E-1 (Sigma, Aichach, D); High-speed homogenizer Ultra-Turrax® T25 (Jahnke & Kunkel 
GmbH & Co. KG, Staufen, D); Atomic Force Microscope Nanoscope IV Bioscope™ 
(Veeco Instruments, Santa Barbara, CA, USA); Freeze-drier Alpha 2-4 LSC (Christ, 
Osterode, D); Rotavapor® R-205 (Büchi, Flawil, CH); Zetasizer® 3000 HS A (Malvern 
Instruments GmbH, Herrenberg, D); for multiphoton fluorescence imaging the 
femtosecond laser imaging system DermaInspect® (JenLab GmbH, Jena, D), equipped 
with a Chameleon laser system (Coherent Inc., Santa Clara, CA, USA) and a 
Hamamatsu PMT(H7732) detector (Hamamatsu Photonics Deutschland GmbH, 
Herrsching am Ammersee, D) was used. 
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2.3.3.  Nanoparticle preparation and characterization 
PLGA nanoparticles loaded with flufenamic acid (FFA NP) were prepared using a 
solvent extraction method. 30 mg of flufenamic acid were dissolved in a solution of 600 
mg of PLGA in 20 ml of ethyl acetate. This organic phase was added dropwise into 20 ml 
of an aqueous phase, containing 1% of PVA as a quasi-emulsifier, under stirring with a 
magnetic stirring bar. The resulting O/W emulsion was homogenized with a high-speed 
homogenizer at 13500 rpm for 10 minutes. To complete the precipitation, water was 
added up to 200 ml under stirring with a magnetic bar. Organic solvent was then 
removed using a rotating evaporator. The resulting nanoparticles suspension was freeze-
dried and stored until use. 
For reference, standard drug-free nanoparticles were prepared in the same way. 
Size and surface morphology of the FFA NP were determined using photon 
correlation spectroscopy (PCS) and atomic force microscopy (AFM). For the AFM 
measurements, a drop of the nanoparticles suspension and hydrogel, respectively, were 
air-dried on a silica wafer. Imaging was done using a silicon cantilever with a spring 
constant of approximately 40 N/m and a resonance frequency of about 170 kHz. The 
scan speed applied was 0.2 Hz. The resolution was 512 × 512 pixels. In order to avoid 
generating sample artefacts the tip loading force was minimized. 
The content of FFA in the particles was determined using the following equation: 
 Whereas FFA Free was determined in the supernatant obtained from a 
centrifuged suspension (23147×g), FFA Total was obtained after a proper extraction of 
the NP suspension using 0.05 M sodium hydroxide solution. The obtained drug 
entrapment was 63.6 % w/w that was calculated using the following equation: 
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Equation 5: Entrapment percentage of drug into nanoparticles 
 
Where mid is the mass of the initial drug used and mfd the mass of the free drug 
detected in the supernatant after centrifugation of the nanoparticle suspension. 
 
2.3.4.  Gel preparation 
Flufenamic acid Natrosol® hydrogel (FFA HG) was prepared with flufenamic acid 
dissolved in water under vigorous stirring. Afterwards, Natrosol® was added in a 
proportion equivalent to 1.5 % (w/w) and stirred overnight until the polymer was 
completely swollen. The absence of crystals was determined by microscopic inspection 
of the gels.  
To prepare a flufenamic acid nanoparticles hydrogel (FFA NP HG) a Natrosol® 
gel (3% w/w) was mixed with an aqueous suspension of the nanoparticles in a 1:1 ratio 
to obtain the same concentration as in FFA HG. The presence and integrity of the 
particles in the gel was confirmed by AFM (see figure 1). In addition, the FFA 
concentration in each gel was verified by HPLC. 
In the same way, a hydrogel containing drug-free nanoparticles was prepared. 
Penetration and permeation experiments were carried out using FFA HG and 
FFA NP HG, each with a drug concentration of 0.12 mg/g. 
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2.3.5.  Skin preparation  
Excised human skin from Caucasian female patients, who had undergone 
abdominal plastic surgery, was used. The Ethical Committee of the Caritas- 
Traegergesellschaft (6th July 1998), Trier, Germany, approved the procedure used. 
Adequate health and no medical history of dermatological disease were required. After 
excision, the skin was cut into 10 × 10 cm2 pieces and the subcutaneous fatty tissue was 
removed from the skin specimen using a scalpel. Afterwards the surface of each 
specimen was cleaned with water, wrapped in aluminium foil and stored in polyethylene 
bags at –26°C until use. Previous investigations have shown that no change in the 
penetration characteristics occurs during the storage time of 6 months [77, 84]. 
Disks of 25 mm in diameter were punched out from frozen skin, thawed, cleaned 
with Ringer solution, and either transferred directly into the Saarbrücken model or used 
to prepare heat separated epidermis sheets for the Franz diffusion cell experiment. 
 
2.3.6.  Heat separated epidermis preparation 
The epidermis was separated placing the thawed and cleaned skin disk in water 
at 60°C for 90 seconds. After that, the skin was removed from the water and placed, 
dermal side down, on a filter paper. The epidermal layer was peeled off from the skin 
using forceps. Before use in the FD-C, the epidermal membrane was pre-hydrated for 1 
h. 
 
2.3.7.  Permeation experiments 
Using a FD-C, experiments were carried out using heat-separated epidermis 
mounted on a cellulose membrane disk. The membrane was positioned between the 
donor and acceptor compartment. As donor 750 µl of preparation and as receptor 12.1 
ml of Soerensen phosphate buffer (pH 7.4) were used. The donor compartment was 
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sealed with aluminium foil and the system was maintained at (32 ± 1) °C in a water bath. 
The acceptor fluid was stirred using magnetic bars at 500 rpm. At predetermined time 
intervals, samples of 1.0 ml were collected from the acceptor medium and replaced 
immediately with fresh buffer solution. Samples were collected until 29 h and analysed 
by HPLC. 
Release experiments were done in the same way but using a cellulose 
membrane to separate donor and receptor compartment. 
 
2.3.8.  Penetration experiments 
Using a SB-M apparatus, a full thickness skin disk was transferred into the cavity 
of a Teflon block on filter paper soaked with Ringer solution to prevent any change in the 
hydration state of the skin. The cavity of the upper Teflon punch was filled with the drug 
preparation and fixed in position. The gap between the two Teflon parts was sealed with 
Plastibase® to avoid water loss from the skin. The whole apparatus was transferred into 
an oven at (32 ± 1) °C for a predetermined incubation time. For details see [54]. 
 
2.3.9.  Skin segmentation  
After the incubation time all the skin specimens investigated with SB-M were 
segmented using tape stripping and cryosectioning method. 
Tape stripping method: At the end of the experiment, the formulation was wiped 
off from the skin surface using cotton. Then the skin piece was transferred to a special 
apparatus where it was mounted using small pins to stretch the tissue. After, the skin 
was covered with a Teflon mask with a central hole of 15 mm in diameter and 
successively stripped with 20 pieces of adhesive tape placed on the central hole. Each 
tape was charged with a weight of 2 kg per 10 seconds and rapidly removed. The 
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samples obtained were pooled according to the following scheme: #1= 1 strip, #2= 1 strip 
#3= 3 strips and #4-6= 5 strips.  
Cryosectioning: After tape stripping, the skin was rapidly frozen in a stream of 
expanding carbon dioxide. A specimen of 13 mm in diameter was punched out from the 
stripped area and transferred into a cryomicrotome. The sections were pooled using the 
following scheme: #1= incomplete cuts, #2-5= 2*25 µm, #6-10= 4*25 µm, #11-15= 6*25 
µm, #16= 8*25 µm, #17= Rest of skin.  
 
2.3.10.  Sample extraction 
The pooled samples were extracted with 0.05 M sodium hydroxide solution and 
shaken during 2 h at room temperature. After that, tape-stripping samples were 
separated from the solid content and directly transferred to the HPLC system. The 
samples of cryosectioning were centrifuged at 456×g for 30 min; afterwards the 
supernatant was separated and transferred to the HPLC system. 
 
2.3.11.  HPLC method 
All the samples were analyzed using the following HPLC conditions: Column 
LiChrospher 100 RP-18, 5 µm, 125*4 mm (Merck, Darmstadt, D); Mobile Phase: 
McIlvaine buffer pH 2.2: Methanol (20:80); Flow rate: 1.2 ml/min; Wavelength: 284 nm; 
Injection volume: 20 µl; Retention time: (3.5 ± 0.2) min. This method has been previously 
validated by Wagner et al [54].   
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2.3.12.  Area under the penetration curve (AUPC) 
 The AUPC was calculated from the curves of penetrated amount per 
cubic centimetre of skin (C = µg/cm3) versus depth (d = µm) obtained from the SB-M 
experiments, using the following equation:  
∑
=
−−=
n
i
iiii ddCdAUPC
1
1)()(  
Equation 6: Area under the permeation curve calculation 
 
2.3.13.  Statistical evaluation analysis 
For statistical evaluation, SigmaStat 3.0.1 was used. 
 
2.3.14.  Multiphoton fluorescence imaging 
Skin samples were punched out, thawed and cleaned before gel application and 
image acquisition. Plain Natrosol® hydrogel, hydrogel containing not loaded 
nanoparticles or containing flufenamic acid loaded nanoparticles respectively, were 
applied to the skin and imaged using multiphoton fluorescence imaging with an 40×/ NA 
1.3 (oil) objective, at excitation wavelength of λ = 720 nm (pulse length 170 fs, repetition 
rate 90 MHz) and an average power of 13 mW. Images were acquired in a time less than 
30 minutes after application of the gel onto the skin. Acquisition time was chosen to be 
25s for a 512×512 pixel image. Starting at the skin surface (z = 0 µm) every 2.3 µm an 
image was recorded to finally obtain a 200×200×46 µm3 stack. The focal plane was 
varied by a piezo driven objective, allowing to survey the entire epidermis down to the 
stratum basale. 
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2.4. RESULTS  
To avoid any inter-individual variability of human skin, all penetration and 
permeation experiments were carried out with skin from the same donor and repeated 6 
times. Only for visualization studies skin from a different donor was used. 
As shown by atomic force microscopy (AFM) in figure 12, the incorporation of NP 
(mean size 328.2 nm, PI 0.16) into a hydroxyethyl cellulose gel has no influence on 
shape and size distribution of the particles, confirming that the hydrogel contained 
undamaged nanoparticles. 
 
 
Figure 12: Atomic force microscopy images of flufenamic acid containing nanoparticles: A) 
aqueous suspension; B) incorporated into Natrosol® a hydrogel 
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2.4.1.  Release experiments 
Release experiments have shown very similar profiles for free and 
nanoencapsulated drug. At approximately 6 hours all the drug content in each 
formulation have been released See figure 13. 
 
Figure 13: Percentage of flufenamic acid released from FFA HG and FFA NP HG. 
 
2.4.2.  Human skin penetration experiments using Saarbrücken model 
Stratum corneum: Between the free and the nanoencapsulated drug no 
statistical significant difference in the amount of flufenamic acid accumulated in the SC, 
expressed as AUPC, was detected at any incubation time. Furthermore, it is remarkable 
that there was a slight decrease of the AUPC for both formulations with increasing 
incubation time (figure 14a). 
Deeper skin layers (viable epidermis and dermis): For these layers statistical 
significant differences in the flufenamic acid amounts between the 2 formulations (t-test, 
P < 0.05) were observed at 3 h and 24 h of incubation time respectively. Interestingly, 
after 3h higher levels were found for the preparation containing the free drug than for the 
NP formulation. In contrast, after 24 h this relation was inverted, i.e. a considerably 
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higher amount of drug has penetrated from nanoparticles compared to the free drug 
(figure 14b). In addition, a decrease compared with the 6 h values for both preparations 
was observed, although the same preparations were used. The reason for these results 
may be addressed to a radial diffusion in the SB-M. Considering that the drug was 
extracted only from samples obtained from a disk of 13 mm (in diameter) of the stripped 
area, not all the drug can be detected. For both preparations FFA was detected in the 
filter paper under the skin, indicative that the sink conditions, which favour the vertical 
diffusion of the drug, were not maintained completely and therefore could influence the 
obtained results. However, one can assume that for both experimental series the effect 
occurs in the same magnitude. Therefore, direct comparison of the nanoencapsulated 
drug preparation and the free drug preparation at this incubation time is still justified.  
 
2.4.3.  Human skin permeation experiments using Franz diffusion cell 
system 
For better comparison, the same time points as chosen in the penetration studies 
(SB-M) were used in the permeation experiments (FD-C). At shorter incubation times (< 
12 h) there were no significant differences in the permeated amount of drug. The levels 
of the free drug formulation tended to be slightly increased, but the differences were 
statistically not significant (figure 15). However, for longer incubation times (24 h and 
later) there was a statistically significant inversion of the drug amount permeated, i.e. 
more drug had permeated from the nanoencapsulated drug formulation compared to the 
free drug formulation. 
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Figure 14: Area under the penetration curve (AUPC) of flufenamic acid penetrated into 
human skin using a Saarbruecken model at different incubation time (n=6). 
 
Figure 15: Permeation of flufenamic acid amount through heat-separated human epidermis 
using Franz diffusion cell system (starred points indicate statistically significant difference). 
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2.4.4.  Visualisation experiments 
Multiphoton fluorescence imaging experiments were carried out using a particle-
free hydrogel, a hydrogel containing drug-free nanoparticles and a hydrogel with FFA 
nanoparticles. As expected, the skin shows an auto-fluorescence and structure 
corresponding to published data [85]. In preliminary studies, it was found that neither 
FFA in solution nor FFA crystals could be visualised in the hydrogel by this technique. 
However, nanoencapsulated FFA yielded a fluorescence signal probably due to the fact 
that the fluorescence of the drug is favoured by the non polar and acidic environment of 
the polymer (figure 5) [52]. The ostensive size of some of the nanoparticles in the 
multiphoton images on the order of a few microns is due to (1) the system resolution (dx 
= dy ≈ 0.4µm, dz ≈ 1µm), (2) partly aggregation and (3) the Brownian motion of the sub-
diffraction-limit-sized particles during image acquisition. Transversal drift of the particles 
led to stretched shapes of their fluorescence spots. 
The multiphoton sections taken at different relative depth to the surface (0 to 50 
µm) of the human epidermis after treatment with the flufenamic acid nanoparticles 
formulation showed a consistent lateral and normal uniform distribution of particles on the 
skin surface and within the dermatoglyphs. But no particles were detected within and 
between the corneocytes (figure 16 E and F). The particle distribution was not indicative 
of accumulation in any skin structure at least after 30 minutes of incubation. See figure 
16. 
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Figure 16: Multiphoton fluorescence imaging of A) plain hydrogel, B) FFA NP HG, C) skin 
with plain hydrogel, D) skin with drug-free nanoparticles hydrogel, E) skin with FFA NP HG 
distributed on the surface and F) skin with FFA NP HG in the dermatoglyphs at a depth of 
16 µm. 
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2.5. DISCUSSION 
Using the Saarbruecken penetration model no differences in drug transport into 
the stratum corneum could be detected for the nanoencapsulated compared to the free 
drug (figure 14). Normally for infinite dose experiments would be expected that the drug 
amount in the SC reaches a plateau while in the DSL the drug amount increases. In our 
experiments it is remarkable that a slight decrease of drug amounts for both preparations 
is visible for the SC. The reason might be a radial spreading of the preparation on the 
skin specimen surface.  
For the DSL the permeation of the drug appeared lower when delivered by 
nanoparticles in comparison to the free drug preparation in both test systems for 
relatively short incubation times (<12 h).  
In contrast to the results obtained at short incubation times, the proportion of drug 
transported into the DSL was inverted after longer incubation times (>12 h). A statistically 
significant higher level of drug was found for the nanoencapsulated drug compared to the 
free drug with both techniques, the FD-C and SB-M (figure 14 and 15). The mechanisms 
how nanoparticles increase the amount of FFA at longer incubation times in the DSL 
remains unclear. Since the overall concentration of the flufenamic acid in the FFA HG 
and in FFA NP HG is equal, this should not affect the drug transport. However, it may be 
speculated that the degradation of the particles leads to some release of acidic 
compounds (lactic and glycolic acid). This acidification of the particles and their 
surroundings favours the non-ionised form of FFA which penetrates the SC better. pH 
changes of the PLGA particles due to the degradation has been reported by Fu et al [86] 
earlier. Furthermore, if particles were able to cross the stratum corneum [80] after a 
certain incubation time, this could also increase the amount taken up. However, 
multiphoton fluorescence imaging does not give any hint to this mechanism at least not 
after short incubation time (30 min).  
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Our attempts to visualise drug transport into the skin by multiphoton fluorescence 
microscopy were restricted to the nanoencapsulated drug, while the free flufenamic acid 
did not yield any fluorescence signal. The distribution of nanoparticles applied to the skin 
appeared to be homogeneous within the hydrogel and followed the structure of the skin 
surface and the dermatoglyphs. No hair follicles or sweat glands were observed, so that 
possible transport of nanoparticles along these structures such as previously reported by 
others [40, 41, 79] could not be confirmed by this study. At least after the relatively short 
incubation time of 30 minutes, no particles were detected within or in between the 
corneocytes. The visualization of drug transport processes for nanoparticles after longer 
incubation times (>12 h) is still ongoing and subject of further investigations. 
In summary, while there were no differences in the SC between free and 
nanoencapsulated drug, such differences became visible at the level of the DSL. After 
shorter incubation times (< 12 h), a significantly higher penetration was obtained with the 
free drug preparation, suggesting that nanoencapsulation causes a slight delay of drug 
transport, whereas, for longer incubation times (> 12 h) the result was inverted and up to 
50% more of drug was transported into the DSL by the nanoparticles compared to the 
free drug formulation. 
 
2.6. CONCLUSIONS 
In this study the effect of the nanoencapsulated flufenamic acid on the skin 
transport was investigated at different incubation times using permeation and penetration 
systems (FD-C and SB-M, respectively). For shorter incubation time (< 12 h) a slight 
delay in the skin transport was observed. In contrast, for longer incubation times (> 12 h) 
the drug transport was enhanced for nanoencapsulated drug compared to the free drug. 
Although not yet fully understood, such observation underscores the potential of 
nanotechnology for transdermal drug delivery. 
  
 
 
 
 
 
 
 
 
CHAPTER 3: MECHANISM OF IMPROVEMENT OF TRANSDERMAL 
DELIVERY BY PLGA NANOPARTICLES 
 
 
 
 
 
 
Parts of this chapter have been submitted for publication in Journal of 
Controlled Release in the article entitled “Human skin permeation using PLGA 
nanoparticles is mediated by local pH changes” (Javiana Luengo, Marc 
Schneider, Karl-Heinz Kostka, Ana M. Schneider, Claus-Michael Lehr, Ulrich F. 
Schaefer) 
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3.1. ABSTRACT  
The aim of this chapter was to investigate the pH influence due to the presence of 
poly(lactide-co-glycolide) (PLGA) nanoparticles in semisolid as well as liquid formulations 
on the epidermal permeation of the anti-inflammatory drug flufenamic acid (FFA). For this 
purpose different vehicles, under non-buffered and buffered conditions, and different 
membranes (human heat separated epidermis and a commercially available 
reconstituted human epidermal model) were tested. Permeation experiments were 
performed using static Franz diffusion cells under occlusion. 
It was observed that the presence of nanoparticles increased drug permeation 
across the skin barrier. This effect was stronger applying drug-loaded nanoparticles. 
Under different temperature storage conditions it has been observed that 
suspensions and not gels containing nanoparticles shown a drop on the total pH of the 
preparations, being time and temperature dependent. The same preparations have 
shown physical evidence of degradation. 
The use of buffered vehicles with different pH values showed the influence of the 
pH on the permeation behaviour of the FFA. An increased permeated amount with lower 
pH was determined suggesting an impact on the environmental pH of the biodegradable 
nanoparticulate carrier system. This drop of pH on the nano-environment of the carrier 
system was demonstrated and visualized using pH sensitive fluorescent probes. 
Having tested the formulations under buffered and non-buffered conditions, it can 
be concluded that the drop of pH due to the presence of PLGA nanoparticles is the 
reason for the observed enhanced permeation of FFA through the epidermal barrier, 
even increasing it more than 10 folds. 
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3.2. INTRODUCTION  
The stratum corneum have been widely acknowledge as the main barrier to 
percutaneous absorption of substances, limiting the drug characteristics only to small, 
moderate lipophilic and highly potent molecules, it is also regarded as the main pathway 
for penetration through the skin. Although several strategies to improve the cutaneous 
delivery of active pharmacological ingredients have been investigated (e.g. ionto- and 
sonophoresis, electroporation, microneedles, supersaturated formulations, micro-
emulsions, liposomes, colloidal polymeric suspensions, penetration enhancers, etc.) the 
cutaneous penetration of highly lipo- and hydrophilic drugs remains a big issue.  
Biodegradable polymers have long been of interest in the controlled release 
technology because of their biocompatibility and bioresorbability by natural pathways, 
and without the need of the removal of the release device. Polymers derived from lactic 
and glycolic acid have the property that when degrading in the body their end-products 
take part in the Krebs cycle, generating atoxic compounds [87, 88]. For this reason they 
are products of high interest in the drug delivery field. Their degradability can be 
regulated according to the proportions of the units of lactic and glycolic acid present in 
every polymer chain, although by the isomers used, as well as, the molecular weight of 
the latter mentioned. The dissolution conditions of the polymeric device could accelerate 
or retard the degradation process. 
Nanoparticles for pharmaceutical use are in a size range between 10 to 1000 nm. 
Their small particle sizes determine a large interfacial area, increasing the number of 
molecules able to be exchanged. Polymeric nanoparticles consist of macromolecular 
materials and can be used as drug carriers [89]. In various applications nanoparticles 
have shown advantages over liposomes on their physical increased stability, drug 
loading capacity, and a controlled release of the active compound [16]. In these devices 
the drug can be entrapped, dissolved, encapsulated or simply attached to the matrix [80]. 
During the last years polymeric nanoparticles have attracted considerable attention as 
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drug delivery devices but only limited biodegradable nanoparticulate systems have been 
investigated to be used on dermal and transdermal delivery.  
The aim of the present work was to elucidate the mechanism how poly(lactide-co-
glycolide) (PLGA) nanoparticles improve the permeation of the anti-inflammatory drug, 
flufenamic acid through the epidermal membrane, considering the results presented in 
the previous chapter which have shown this effect using PLGA nanoparticles. Following 
this objective, permeation experiments using loaded and not loaded nanoparticles were 
performed to examine if the drug must be incorporated into the particle to have the 
enhancing effect; also the influence of the particle size of loaded nanoparticles was 
studied. To investigate the effect of the nanoparticles-containing formulations under 
normal application conditions, finite dose regime was used. The influence of the 
presence of hair follicles was studied using human heat-separated epidermis and a hair 
follicle-free reconstituted human epidermal barrier. To investigate the pH effect of the 
nanoparticles on the permeation improvement through the epidermal barrier, 
formulations were tested under buffered or non-buffered conditions. 
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3.3. MATERIALS AND METHODS 
 
3.3.1.  Materials 
Hydroxy ethyl cellulose (HEC) Natrosol® 250 M (Aqualon, Hercules Inc., DE, 
USA), Flufenamic acid, modification II (Kali-Chemie Pharma, Hannover, D), Poly(D,L-
lactide-co-glycolide) (50:50) with a molecular weight of 40000 to 75000 Da (Sigma 
Chemical Co., St. Louis, MO, USA), Polyvinyl alcohol (PVA) Mowiol® 4-88 (Kuraray 
Specialities Europe GmbH, Frankfurt, D), Ringer solution, McIlvaine citric acid phosphate 
buffer at different pH values, Phosphate buffer (pH 6) (all components from Merck, 
Darmstadt, D), Sodium hydroxide solution (0.1 M) , Hydrochloric acid (0.1M) (Grüssing 
GmbH, Filsum, D), Methanol Chromasolv® (Sigma-Aldrich GmbH, Seelze, D), Ethyl 
acetate (Fluka Chemie GmbH, Bucks, Switzerland), Cellulose membrane MWCO 12000 
– 14000 Da (Medicell International Ltd., London, LX, USA) were used as obtained from 
the suppliers, Arabic gum (Caeser & Lorentz, Hilden, D), Gelatine A (Dt. Gelatine 
Fabriken, Eberbach, D), n-Octanol and Propanol (Merck, Darmstadt, D), LysoSensor™ 
Green DND-189 (Invitrogen GmbH, Karlsruhe, D) were used as obtained from the 
suppliers. 
 
3.3.2.  Equipment 
HPLC System: ChromeleonTM Version 6,5 SP2, build 968; P580 Pump; ASI-100 
automated sample injector; STH 585 Column oven; UVD 170S Detector (Dionex Softro 
GmbH, Germering, D); Franz diffusion cell type 6G-01-00-15 (Perme Gear, Riegelsville, 
PA, USA); High-speed homogenizer Ultra-Turrax® T25 (Jahnke & Kunkel GmbH & Co. 
KG, Staufen, D); Rotavapor® R-205 (Büchi, Flawil,CH); Zetasizer® 3000 HS A (Malvern 
Instruments GmbH, Herrenberg, D), Confocal laser scanning microscope (CLSM) MRC 
1024 (BioRad/Carl Zeiss AG, Jena, D), Atomic Force Microscope Nanoscope IV 
Bioscope™ (Veeco Instruments, Santa Barbara, CA, USA). 
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3.3.3.  Nanoparticles preparation and characterization 
PLGA loaded and drug-free nanoparticles were prepared by solvent extraction 
method, and characterized using photon correlation spectroscopy (PCS) and atomic 
force microscopy (AFM), for further details please refer to Section 2.3.3.  
 
3.3.4.  Microparticles from PLGA and arabic gum/gelatine A 
The PLGA microparticles were prepared using the same composition like the 
nanoparticles but modifying the homogenization conditions (speed: 8000 rpm and time: 2 
minutes).  
In brief, the preparation of the arabic gum/gelatine A microparticles was done by 
dissolving homogenously gelatine A in distilled water. Then n-octanol (several drops) and 
the dissolved arabic gum were added. Afterwards, distilled water at 50°C was added and 
the pH adjusted to 4 using acetic acid. After a cooling step over night, the particles are 
re-dispersed in isopropanol for post-curing and dried. 
 
3.3.5.  Non-buffered gel preparations 
Flufenamic acid HEC hydrogel (FFA HG) was prepared with flufenamic acid 
dissolved in water and a minimal amount of sodium hydroxide solution to accelerate the 
dissolution (that was neutralized later on using hydrochloric acid solution) under vigorous 
stirring. Afterwards, HEC was added in a proportion equivalent to 1.5% (w/w) and stirred 
overnight until the polymer was completely swollen. The absence of crystals was 
determined by microscopic inspection of the gels.  
For the preparation of the NP containing gels, the original NP suspension was 
concentrated by centrifugation as follows: volumes of 20 ml of fresh prepared 
nanoparticles suspension were centrifuged at 2468xg per 5 min, 15 ml of the supernatant 
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were removed and the particles re-suspended, and the suspension drug content 
determined and adjusted. 
To prepare a flufenamic acid nanoparticles hydrogel (FFA NP HG) a HEC gel 
(3% w/w) was mixed with a concentrated aqueous suspension of the nanoparticles in a 
1:1 ratio to obtain the same concentration as in FFA HG.  
A hydrogel containing drug-free nanoparticles (FFA HG + DF-NP) was prepared 
using a doubled flufenamic acid and HEC concentration, prepared as described for FFA 
HG and mixed with a concentrated drug-free nanoparticles suspension in a proportion 
1:1.  
To the nanoparticles-containing-gels, the same amounts of NaOH and HCl 
solutions as in FFA HG were added. The presence and integrity of the particles in the gel 
was confirmed by AFM.  
Permeation experiments were carried out in quadruplicate using FFA HG, FFA 
NP HG and FFA HG + DF-NP, each with a drug concentration of 0.125 ± 0.006 mg/g. 
The pH of the preparations was 5.4 ± 0.1. 
 
3.3.6.  Flufenamic acid saturation concentration in different solutions 
 The studies regarding the concentration of saturation in varying vehicles 
were performed as follows: 500 mg of flufenamic acid were placed in a 500 ml volumetric 
flask and Soerensen phosphate buffer (pH 6.0) and McIlvaine buffer solutions at pH 
values between 3.4 and 7.4 (for composition, please refer to [90]) were added. Every 
mixture was stirred at 500 rpm during 48 h at 32 ± 1°C and left sediment during 12 h at 
the same temperature. Three samples of 10 ml each were taken from each flask and 
filtered through OptiFlow-PTFE filter (0.2 µm) at the same temperature. The first 7.5 ml 
were discarded and the last 2.5 ml collected in a separate flask. One millilitre of the 
filtrated solution was diluted to 100 ml with NaOH 0.05 M and analysed by HPLC. 
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3.3.7.  Buffered gels preparation  
Buffered gels were prepared as described above using HEC and buffer solution 
at different pH (Soerensen phosphate buffer pH 6.0) instead of water, and the respective 
flufenamic acid, additional drug-free nanoparticles or loaded nanoparticles. 
Permeation experiments were carried out by quadruplicate using FFA HG, FFA 
NP HG and FFA HG + DF-NP, each with a drug concentration of 0.125 ± 0.006 mg/g. 
The pH of the preparations was those of the respective buffer solution with an error of ± 
0.1 unit. 
 
3.3.8.  Flufenamic acid solutions and NP suspensions 
 
Non-buffered formulations 
A concentrated solution of flufenamic acid of 98.85 µg/ml was prepared in NaOH 
0.04 M.  
Flufenamic acid non buffered solution (FFA sol), loaded nanoparticles non 
buffered suspension (FFA NP), and solution containing drug-free nanoparticles non 
buffered suspension (FFA + DF-NP) were prepared mixing the components described in 
table 1: 
 
 FFA sol FFA NP suspension 
FFA solution 
+ DF-NP 
suspension 
FFA concentrated solution 40.464 ml -- 40.464 ml
HCl 0.1 M 1.480 ml 1.480 ml 1.480 ml
NaOH 0.04 M -- 40.464 ml --
FFA NP concentrated suspension9 -- 25.536 ml --
DF-NP concentrated suspension 9 --  25.536 ml
Deionised water to 100 ml 100 ml 100 ml
 
Table 1: Compositions of flufenamic acid non-buffered formulations. 
                                                 
 
9 Prepared as described in section 3.3.5 
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3.3.9.  Buffered formulations 
One hundred millilitres of McIlvaine concentrated buffers were prepared by the 
composition describe in table 2: 
 
 pH 5.4 pH 6.4 pH 7.4 
Citric acid monohydrate 0.2 M 44.7 31.4 9.8 
Disodium phosphate dihydrate 0.4 M 55.3 68.6 90.2 
 
Table 2: Composition of McIlvaine buffer solutions for flufenamic acid buffered preparations 
 
Flufenamic acid solution (FFA sol), loaded nanoparticles suspension (FFA NP) 
and containing drug free nanoparticles buffered formulations were prepared as follows: 
Buffer solution and water were mixed with the drug and stirred overnight to allow the drug 
to be dissolved, afterwards nanoparticles concentrated suspension was added to the 
mixture (when corresponds). See composition in table 3. 
 
 FFA sol FFA NP suspension 
FFA solution 
+ DF-NP 
suspension 
 FFA sol FFA NP FFA + DF-NP 
Concentrated buffer 50.000 ml 50.000 ml 50.000 ml
Flufenamic acid 4000 µg 4000 µg
FFA NP concentrated suspension10 25.536 ml
DF-NP concentrated suspension10 25.536 ml
Deionized water to 100.000 ml 100.000 ml 100.000 ml
 
Table 3: Composition of flufenamic acid buffered preparations. 
 
For determination of the drug concentration all preparations were extracted and 
diluted with NaOH 0.05 M and samples were analysed by HPLC.  The concentration of 
all liquid formulations was in the range of 37.6 ± 1.9 µg/ml. 
                                                 
 
10 Prepared as described in section 3.3.5 
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3.3.10.  Skin preparation 
See method described in section 2.3.5. 
 
3.3.11.  Heat separated epidermis preparation 
See method described in section 2.3.6. 
 
3.3.12.  Degradation of nanoparticles hydrogels and suspension 
Degradation of particles was studied in hydrogels and suspension by visualization 
using atomic force microscopy (AFM) and at the same time pH of the preparations was 
measured using an electrode pHmeter. The later mentioned formulations were stored at 
different conditions: 4°C, room temperature and 32°C, protected from the light.  Samples 
at different time points were collected during several weeks and analysed. 
 
3.3.13.  Permeation experiments 
Using static Franz diffusion cells (FD-C), experiments were carried out using 
heat-separated epidermis mounted on a cellulose membrane disk, or reconstituted 
epidermis, as membrane. The membrane was positioned between the donor and 
acceptor compartment. As donor 0.75 ml of the gel or 1 ml of solution or NP suspension 
for infinite dose experiments, and approx. 18 mg of gel for finite dose experiment (exact 
weight was noticed and used for the calculations). As receptor 12.1 ml of Soerensen 
phosphate buffer (pH 7.4) were used. The donor compartment was sealed with 
aluminium foil and the system was maintained at (32 ± 1) °C in a water bath. The 
acceptor fluid was stirred using a magnetic bar at 500 rpm. At predetermined time 
intervals, samples of 0.3 ml were collected from the acceptor medium and replaced 
immediately with fresh buffer solution. Samples were collected until 30 h and analysed 
by HPLC. 
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3.3.14.  HPLC method 
See method described in section 2.3.11.   
 
3.3.15.  Determination of apparent permeation coefficient  
Apparent permeation coefficient (Papp) values were calculated from an equation 
derived from the Fick’s first law assuming perfect sink conditions in the system (i.e. the 
FFA concentration does not exceed the 10% of its saturation concentration in the 
receptor compartment), see equation 1. The flux at steady state (Jss) was calculated from 
the slope of the linear portion of the cumulative amount per area unit versus time plots 
(for HSE the points between 3 and 9 hours and for SkinEthic® points between 2 and 6 
hours were considered). Cv parameter corresponds to the concentration of the donor. 
v
ss
app C
JP =
 
Equation 7: Apparent permeation coefficient of the epidermal barrier using infinite dose 
under steady state conditions 
 
3.3.16.  Enhancement factor calculation 
Enhancement factor (E) was calculated using the Papp values of the different 
preparations (n) respect to the dissolved drug containing formulation (FFA HG or FFA sol 
as reference (ref) when corresponds). 
ref
app
n
app
P
P
E =
 
Equation 8:  Enhancement factor calculation using the apparent permeation coefficient of 
the different formulations respect to that containing dissolved drug 
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3.3.17.  Local pH measurements using confocal laser scanning microscopy 
measurements 
For the measurement of the local pH the particle suspensions’ pH were adjusted 
roughly to pH = 7 using sodium hydroxide. Hereafter, 10 µl of the suspension were mixed 
with 10 µl of a 0.1 mM LysoSensor™ solution. The mixture was given on a microscope 
slide and sealed with a cover slip using nail polish. The fluorescence measurements 
were performed using the 488 nm line of the argon/krypton laser line and a band pass 
filter (522/35) for each of the particle suspensions. Transmission light images were taken 
using a conventional light bulb with the red channel of the CLSM. 
 
3.3.18.  Statistical evaluation 
For statistical evaluation, SigmaStat 3.0.1 was used. ANOVA test were run using 
“all pairwise comparison procedure” (Holm-Sidak method). Significance level p<0.05. 
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3.4. RESULTS AND DISCUSSION 
 
3.4.1.  Infinite dose permeation experiments using hydrogels and heat 
separated human epidermis  
Infinite dose permeation experiments using FFA hydrogels containing the drug as 
dissolved form, either in the presence or in the absence of drug-free NP, or as drug 
loaded NP, were performed to investigate the influence of nanoparticles on the dermal 
permeation of the highly lipophilic drug, flufenamic acid. The high lipophilicity of the drug 
(log P = 4.88) [52] and its ability to dissociate under dermal physiological conditions (pKa 
= 3.9) [53] makes it a good candidate to be absorbed through the skin.   
As shown in figure 17 an increase in the permeation of flufenamic acid from a 
hydrogel through the complete epidermis into an aqueous medium was observed when 
the drug was loaded into PLGA nanoparticles. When drug-free nanoparticles were co-
administered an intermediate effect, between dissolved drug and loaded nanoparticles, 
was observed. At the same time, the particle size seemed to have a minor influence in 
the permeation profile of the drug when loaded nanoparticles were used. 
 
Figure 17: Heat separated human epidermis permeation profiles of flufenamic acid using 
infinite dose regime of non buffered hydrogels containing: dissolved drug (FFA HG), loaded 
nanoparticles of different size (FFA NP HG), and dissolved drug with drug-free 
nanoparticles (FFA HG + DF-NP). 
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Several explanations for the increased permeation might be possible: (i) the 
nanoparticles are able to cross the epidermis through the hair follicles (27 ± 3 µm in 
diameter), inducing a higher permeated amount of FFA in the receptor medium. Hair 
follicle targeting using inorganic and polymeric nanoparticles, has been demonstrated by  
several authors, as Lademann and Toll [41, 44], as one of the mechanisms how 
nanoparticulate carriers could increase the drug delivery into the deeper skin layers. In 
the case of the drug-free nanoparticles, their more lipophilic nature compared with the 
hydrogel might lead to an adsorption of drug on the surface of the nanoparticles. In this 
form they could cross the epidermal barrier using the same pathway than the loaded 
ones; (ii) on the other hand, particles could release some degradation products (lactic 
and glycolic acid) to the hydrogel that could change the ionization state of the drug or 
modify the permeability characteristics of the stratum corneum, improving the permeation 
of FFA through the epidermal barrier. To evaluate those hypothesis further additional 
experiments were carried out. 
  
3.4.2.  Infinite dose permeation experiments using hydrogels and 
reconstituted human epidermis (Skinethic®)  
Trying to elucidate the mechanism how the PLGA nanoparticles increased the 
permeation through heat separated epidermis, experiments were carried out using a 
reconstituted human epidermal equivalent, SkinEthic®, as barrier and the same 
hydrogels containing different sized FFA NP, dissolved drug and the latter mentioned 
containing drug-free nanoparticles. SkinEthic® is a human reconstructed epidermal 
model, highly permeable [91-93] and devoid of hairs and hair follicles. If the penetration 
enhancement of FFA in the presence of NP as observed in natural human HSE involves 
hair follicles, lower or no differences among the formulations were expected for the 
reconstituted human epidermis. But in contrast to these considerations, FFA permeation 
differences were accentuated with respect to those observed using human HSE when 
nanoparticle-containing formulations were used (see figure 18). Now FFA permeation 
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reached almost 100% of the applied dose permeated. The described results suggested 
that the mechanism proposed by Lademann and Toll was not exclusively responsible for 
the increased permeation using nanoparticles. 
 
 
Figure 18: Reconstructed human epidermis (SkinEthic®) permeation profiles of flufenamic 
acid using infinite dose regime of: dissolved drug hydrogel (FFA HG), loaded nanoparticles 
hydrogel of different size (FFA NP HG), and dissolved drug with drug-free nanoparticles 
hydrogel (FFA HG + DF-NP) 
 
3.4.3.  Finite dose permeation experiments using hydrogels and heat 
separated human epidermis 
Finite dose permeation experiments were performed using different sized FFA 
NP HG compared with free drug containing HG. Again the same trend as in infinite dose 
experiments was found, i.e. a higher permeation for the nanoparticle-containing 
formulation. However, the differences failed to reach statistical significance (see figure 
19). 
Only weak differences might be a result of the rapid depletion of the donor phase 
due to the small amount applied. 
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In view of the fact that some similar penetration enhancement was observed both 
for natural and reconstituted (i.e. follicle free) epidermis, as well as under infinite and 
finite dose conditions, led us to the following hypothesis. The degradation of the 
nanoparticles generates a lower pH microenvironment around the particles, favouring the 
non-ionized form of the drug, which is able to cross the barrier easier than the ionic form. 
This idea is supported by the results obtained by different research groups during the last 
years, detailed as follows: (i) PLGA microparticles develop a strongly acidic core when 
particles are incubated in a buffered medium over several days [86]; (ii) the smaller the 
size of the carrier is (e.g. 15 ↔ 40 nm), the faster the diffusion of degradation products 
(lactic and glycolic acid) to the medium become [94, 95]; (iii) PLGA 50:50 has a very fast 
degradation rate which can be influenced by the medium conditions (e.g. pH, 
temperature) [87, 88, 96]; (iv) the degradation products (lactic and glycolic acid) are able 
to modify the permeation characteristics of the epidermal barrier [97, 98]. To substantiate 
this hypothesis, the following experiments were carried out to elucidate if the pH 
generated by the nanoparticles has any influence on the permeation through the 
epidermal barrier. 
 
Figure 19: Human heat separated epidermis permeation profiles using finite dose regime of 
dissolved drug (FFA HG), different size loaded nanoparticles (FFA NP HG), and dissolved 
drug with drug-free nanoparticles (FFA HG + DF-NP) containing hydrogels. 
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3.4.4.  Flufenamic acid saturation concentration in different solutions 
 
Solvent Saturation concentration (µg/ml) 
Ionized percentage 
(%) 
Water 5.8 ± 0.8  
Soerensen buffer pH 6.0 29.4 ± 0.4 99.21 
pH 3.4 1.8 ± 0.2 24.00 
pH 4.4 5.6 ± 0.5 75.97 
pH 5.4 43.1 ± 1.8 96.93 
pH 6.4 383.4 ± 14.2 99.68 
Mc Ilvaine buffer 
pH 7.4 2896.1 ± 55.9 99.97 
Soerensen buffer  pH 7.411 2059.5 ± 21.6 99.97 
 
Table 4: Saturation concentration and ionized percentage of flufenamic acid in different 
solvents at 32 °C (mean ± SD) 
 
The saturation concentrations in different solutions at different pH values were 
determined, and the theoretical percentages of ionized drug at every pH were calculated. 
The results are described in table 4: 
It can be seen that at different pH values the solubility of the drug changes as well 
as its thermodynamic activity, a fact that will influence the drug transport through the 
epidermis. 
 
3.4.5.  Formulation pH and particle degradation 
The pH values were measured in non-buffered suspension and gel during two 
weeks after preparation to determine the influence of the storage temperature on the 
stability of the preparation.  It was noticed that in suspensions the pH values dropped of 
one unit when the formulation was stored at 32°C, an intermediate effect was observed 
                                                 
 
11 Data obtained from Henning, A. 2005 
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at room temperature, and only a slight drop of the pH of 0.1 units when stored at 4°C 
(see figure 20A) was found. 
When pH was measured in the gels, stored under the same conditions, it was 
noticed that the decrease on pH was not as evident as has been observed with the 
suspension (see figure 20B).This could be due to the reduced mobility of the hydrogen 
ions in the gel that cannot be detected by the electrode or that the degradation of the 
polymer is not so fast as in suspension. 
Visualization studies using AFM has shown that the degradation process in gels 
is not as fast as in the suspension at 32 °C (Figure 21)12. At 4 °C the rate of degradation 
is much slower and at the end of the experience particles have the same appearance 
than at week 1 (data not shown).  At week 4, also pore formation and fusion of the 
particles appeared as has been observed before by Panyam et al using protein loaded 
PLGA nanoparticles. Finally at week 6, no particles were found in the suspension, and in 
the gel there were still some particles in the last degradation stages. Panyam et al have 
demonstrated that an increase in the particle size results in a decrease in the 
degradation rate of the particles. Moreover, and a biphasic degradation profile with a 
higher initial degradation rate followed by a second slower phase, were pores and fusion 
of the particles was observed, probably due to the easier diffusion of the degradation 
products out of the particles [99]. It may be speculated that particularly the initial fast 
degradation could influence the permeation of flufenamic acid through the epidermal 
barrier. 
 
  
 
                                                 
 
12 Mrs. Noha Nafee (Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University) 
is thanked for the atomic force microscopy pictures 
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Figure 20: pH variation according to the storage temperature versus time of FFA NP 
suspension (A) and FFA NP containing hydrogel (B) 
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Figure 21: Atomic force microscopic pictures of nanoparticles degradation in suspension (S) 
and hydrogel (G) media at different time and temperature conditions 
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3.4.6.  Infinite dose permeation studies using buffered hydrogels and heat 
separated human epidermis 
 
To examine the influence of the pH and buffered systems, permeation 
experiments were carried out using buffered gels containing the same amount of drug 
but with adjusted pH values. When hydrogels containing Soerensen phosphate buffer at 
pH 6.0 were investigated an extremely high increase in the permeation, especially using 
the formulation containing the dissolved drug (see figure 22) was found. Two possibilities 
could be responsible for those results: the buffer compensated the effect of the 
nanoparticles on the skin or the buffer system influenced the barrier properties of the 
skin, inducing a higher permeation of the dissolved drug. 
Under steady state conditions apparent permeation coefficient values (Papp) were 
calculated from the above mentioned infinite dose experiments (see table 5). Comparing 
the Papp values it was possible to observe that: non-buffered conditions, the use of HSE 
and the application of loaded nanoparticles increased the permeation approximately 8 
fold compared to the administration of dissolved drug while the application of non loaded 
nanoparticles increased it only 3 fold. When reconstituted human epidermis was used 
the increase in flux was approximately 50 fold with loaded nanoparticles and almost 30 
fold with non-loaded ones. When a buffered system and HSE was used an unclear 
tendency (pH 6) of the effect of the particles presence was observed. These results 
suggest that buffer systems are able to compensate the effect of the nanoparticles on the 
skin permeation of the drug. 
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Figure 22: Human heat separated epidermis permeation profiles of a pH 6.0 buffered 
hydrogel using infinite dose regime of preparations containing flufenamic acid as dissolved 
drug (FFA HG), loaded nanoparticles (FFA NP HG), and dissolved drug with drug-free 
nanoparticles (FFA HG + DF-NP) 
 
 
 
FFA HG FFA NP HG (286 nm) 
FFA NP HG 
(486 nm) 
FFA HG + 
DF-NP  
Papp Papp E Papp E Papp E 
HSE 0.6 ± 0.3 4.7 ± 0.9* 8 7.6 ± 3.0* 13 1.8 ± 0.6 3 
SE 
Non 
buffered
pH 5.4 1.1 ± 1.2 48.5± 1.8* 44 77.0 ± 3.7* 70 31.2 ± 1.6* 28 
HSE BufferedpH 6.0 24.4 ± 2.7 18.3 ± 6.0 0.8 ---- --- 14.7 ± 3.1* 0.6
 
Table 5: Apparent permeation coefficient (Papp) of flufenamic acid through human heat 
separated epidermis (HSE) and reconstituted human epidermal model, SkinEthic® (SE), and 
enhancement factor (E) respect to the dissolved drug containing formulation (FFA HG), 
using hydrogels in infinite dose regime. Papp values are expressed as 10-6 cm/s (mean ± 
SD). Statistical significant difference is marked with a star. 
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3.4.7.  Permeation studies using non-buffered and buffered solutions and 
nanoparticles suspensions 
To rule out the influence of the gel forming agent over the skin permeation it was 
decided to apply a solution and/or nanoparticles in suspension in a non-buffered and 
buffered form at different pH values. 
Similar results to those observed using non-buffered hydrogels where obtained 
when non-buffered solution or NP suspension were tested (see figure 23 NB): a higher 
permeation using loaded nanoparticles, an intermediate effect when non-loaded particles 
were added to a drug solution and the lowest permeation was obtained with the drug in 
dissolved form. These results confirmed that the gel forming agent has no influence on 
the permeation of FFA through the epidermal barrier. 
 
Figure 23: Human heat separated epidermis permeation profiles using flufenamic acid 
solution (FFA sol), FFA solution containing drug-free nanoparticles suspension (FFA sol + 
DF-NP susp) and loaded nanoparticles suspension (FFA NP susp) as non-buffered 
preparations (NB) and buffered at different pH values 
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The summarized results were compared with those obtained using the same 
above mentioned preparations at different pH values (see figure 23). In all cases, a 
decrease of the permeation in combination with an increase of the pH value was 
observed. Additionally it was found that when non-buffered preparations were used, 
permeation of the flufenamic acid solution show a similar permeation to the higher pH 
value (pH 7.4), the solution containing drug-free nanoparticles to the intermediate pH 
value (pH 6.4) and the loaded nanoparticles to those with the lower pH value (pH 5.4). 
Considering that the measured pH of the non-buffered preparations was in the 
range of 5.8 ± 0.2 these results confirmed the hypothesis that the nanoparticles have an 
influence on the pH and hence modify/influence the permeation behaviour of the drug. 
As proved by Fu et al, PLGA particles suspended in a buffered medium are able to 
create an inner acidic environment due to the polymer degradation which is more 
pronounced for smaller than larger particles [86]. Additionally, a change of the acidity 
was demonstrated for non-buffered systems over a time period of several days. 
Therefore, these carriers might be able to create an external micro-surrounding acidic 
environment that could increase the amount of non-ionized drug available for the 
permeation through the epidermal membrane when the nanoparticles are in contact with 
it. 
The Papp of flufenamic acid through the HSE using non buffered solutions and 
suspensions have approximately the same magnitude than with the hydrogel 
preparations (see table 6), increasing approx. 8 and 3 folds, respectively, when loaded 
nanoparticles and drug-free nanoparticles were used (values relative to the flux obtained 
with flufenamic acid solution). When buffered preparations were used no differences 
among them at one determined pH were observed. When the same preparation at 
different pH values was compared in all cases, i.e. flufenamic acid solutions, loaded 
nanoparticles suspensions and solutions containing drug-free nanoparticles, an increase 
of approx. 4 and 10 or more folds was observed when pH decrease around 1 or 2 pH 
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units. These findings indicate that the pH which was generated by the presence of the 
particles in the non-buffered systems induces a low pH region only in the interior of the 
particle or the close surrounding. 
Some authors investigated the mechanism how α-hydroxy acids can reduce the 
stratum corneum cohesion, favouring the increase of permeation of drugs across the 
skin. E.g. Sebastiani et al have studied the effects of lactic acid on the skin permeation 
using rabbit skin. Three drugs with different physicochemical characteristics were 
examined proving that only the passive permeation of ibuprofen, an anionic drug 
(characteristic present also in flufenamic acid), was affected by the presence of lactic 
acid, increasing its permeation by several-fold, suggesting an increase in the partitioning 
from the formulation to the skin, and assuming that the diffusion pathway remained 
unchanged [98].  
 
 FFA solution FFA NP suspension FFA solution + DF-NP suspension 
 Papp Papp E Papp E 
Non 
Buffered 
pH 
5.8  1.1 ± 0.2 10.0 ± 0.7* 9 2.4± 1.1* 2 
pH 
5.4 11.2 ± 2.0 7.4 ± 0.5* 0.7 6.6 ± 1.3* 0.6 
pH 
6.4 2.9 ± 0.5 2.2 ±  0.3 0.8 2.0 ± 0.4* 0.7 Buffered 
pH 
7.4 0.7 ± 0.2 0.6 ± 0.8 0.9 0.3 ± 0.1 0.4 
 
Table 6: Apparent permeability coefficient (Papp) of flufenamic acid through human heat 
separated epidermis using a solution, a suspension of loaded NP or a solution containing 
drug-free NP, and enhancement factor (E) respect to the dissolved drug containing 
formulation (FFA solution). Papp values are expressed as 10-6 cm/s (mean ± SD). Statistical 
significant difference is marked with a star. 
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3.4.8.  Investigation of the nanoparticles surface pH changes 
To investigate the possible micro-surrounding acidic environment experiments 
using confocal scanning microscopy were performed. The pH change might take place 
only in the very close (nano-) environment of the particles. However, the resolution is 
limited because the optical transfer function will depict objects smaller than the resolution 
at a dimension which equals the so-called “Airy disc”. For the application of fluorescence-
based methods such as pH-sensitive dyes the local resolution is therefore also limited 
and will exceed the extension of the area where the pH change might take place. To 
overcome these problems regarding the particles, we used PLGA microparticles in the 
range of several micrometers. This facilitated the investigation of the pH on the surface 
only. As a negative control arabic gum/gelatine A microparticles were deployed. The use 
of a dye like the LysoSensor® enables one at least to visualize if different pH values are 
established even though the precise local determination is not accessible. The 
LysoSensor® dyes are known as acidotropic compounds. For pH-values above the pKa 
the dye is unprotonated and the fluorescence is quenched. Therefore, the dye chosen 
exhibits practically no fluorescence in neutral surrounding. In acidic environment the 
molecules are protonated and the fluorescence quenching is relieved; light emission is 
strongly increased. The images depicted in figure 6 reveal a strong fluorescence around 
the microparticles and indicate that our assumption regarding the particles’ pH is correct. 
Image 24A) reveals the presence of the arabic gum/gelatine A particles in transmission 
light whereas in 24B) no fluorescence can be seen e.g. the particles do not change the 
pH of the dye solution. For the PLGA micro- and nanoparticles testing the background 
fluorescence was reduced, pre-setting the pH to approximately 7 (The situation is 
sketched in fig. 24C: particles in a slightly fluorescent solvent). The result changes 
completely exposing the PLGA particles to the same surrounding and measuring 
conditions as described before. An intense fluorescent signal (fig. 24 D and E) was 
observed. Due to the resolution limits, PLGA microparticles were used to demonstrate 
the location where the fluorescence is originated from. The microparticle fluorescence 
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discloses that the light is emitted from/or close to the surface of the particles. The inner 
particle shows fading fluorescence indicating the absence of fluorescent molecules and 
due the optical transfer function of the microscope. For the PLGA nanoparticles used 
throughout the other experiments the fluorescence is observed as well but due to their 
size only fluorescent spots are visible (fig. 24E). The results indicate clearly the different 
pH values at the particles’ surface or close environment compared to other particles13. 
 
 
Figure 24: Fluorescence images obtained immersing different particle fractions into the pH 
sensor solution. Transmission light image to detect the presence of the arabic gut/gelatine A 
paricles (A) and the corresponding fluorescence image (B). PLGA microparticles show 
green fluorescence localized at the surface of the particles or the close surrounding (D). In 
the case of nanoparticles fluorescent spots were observed (E). To highlight the particles the 
color coding was changed so that the particles appear as black spots on a pink background. 
The situation was sketched to illustrate the experimental condition (C, F) 
 
                                                 
 
13 Dr. Marc Schneider and Ms. Ana M. Schneider (Department of Biopharmaceutics and Pharmaceutical 
Technology, Saarland University) are thanked for the confocal laser microscopy pictures. 
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3.5. CONCLUSIONS 
The increased permeation of flufenamic acid through the epidermal layer under 
different conditions indicated that PLGA nanoparticles improve its transdermal delivery. 
The results suggest that these carriers have a pH effect that influence the ionization state 
of the drug and could improve the concentration gradient from the stratum corneum to 
the dermal side of the barrier as well as have a penetration enhancing effect due to the 
degradation products. 
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CHAPTER 4: IN VIVO ABSORPTION OF FLUFENAMIC ACID USING 
DERMAL MICRODIALYSIS: THE EFFECT OF PLGA NANOPARTICLES - 
PRELIMINARY STUDY 
 
 
 
 
 
 
The experiments presented on this chapter were made in collaboration with Prof. 
Dr. Carlos von Plessing (Departamento de Farmacia) and Prof. Dr. Jacqueline 
Sepúlveda (Departamento de Farmacología) from Universidad de Concepción, Chile.  
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4.1. ABSTRACT 
It has been demonstrated in vitro that PLGA nanoparticles are able to improve 
the permeation and penetration of drug through the skin. In order to obtain a first insight 
in the pharmacokinetic profile in vivo, skin microdialysis experiments were carried out. 
Rats were chosen as model to get a first approach of the absorption of flufenamic acid 
using non-buffered hydrogel containing: dissolved drug, loaded nanoparticles or a 
mixture of dissolved drug and drug-free nanoparticles.  
Unfortunately, no concluding results were obtained from the experiments 
performed, indicating that many of the experimental parameters must be adjusted to get 
more information about the flufenamic acid pharmacokinetic  using PLGA nanoparticles 
as transdermal carrier.  
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4.2. INTRODUCTION 
As shown in chapters 2 and 3, in vitro experiments the permeation through heat 
separated epidermis, using two-compartment static Franz-type diffusion cells (FD-C), 
and the penetration into full thickness skin, using Saarbruecken model (SB-M), of the 
model drug flufenamic acid, a highly lipophilic drug, was improved by the use of loaded 
and drug free nanoparticles. Therefore, arises the question to what extent this effects will 
persist under in vivo conditions. 
Among the most critical limitations of the last mentioned in vitro methods is the 
lack of elimination routes in terms of vascular system and viable metabolising enzymes, 
alterations of the stratum corneum (SC) due to the water uptake and the determination of 
permeation instead of penetration, last two apply in case of FD-C. 
In another hand, to obtain clinically relevant information about the 
pharmacokinetics profiles in the skin, in vivo techniques must be applied. One of the 
most used techniques has been tape stripping, technique which removes the SC cell 
layers by consecutive adhesion of tape peaces. Another techniques such as, suction 
blisters, tissue biopsy and dermal imaging techniques such as confocal laser scanning 
microscopy have been also used. Their main disadvantages are that only assesses the 
penetration of the drug into the SC, which normally is not the target of dermal drug 
delivery, and only determine a single concentration-time point. Additionally they need a 
large number of sampling sites on a particular subject, therefore increasing the 
invasiveness involved [67, 100].  
During the last decade microdialysis has been successfully applied to assess 
cutaneous drug delivery of numerous substances. This technique has been shown to be 
minimally invasive and supply pharmacokinetic information directly in the target organ for 
cutaneous drug delivery with high temporal resolution without further intervention with the 
tissue after implantation. This technique uniquely enables the assessment of drug levels 
directly in the dermis and appears as a very sensitive method to investigate minor 
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differences in cutaneous drug delivery. It has been indicated that cutaneous microdialysis 
in rats may be useful for prediction of dermal pharmacokinetic properties of novel 
drugs/topical formulations in man. In the assessment of bioequivalence in terms of 
absorption rate by in vivo microdialysis appears to correlate well with the established in 
vitro FD-C assessment of permeation rates for formulations with the same drug. 
Assessment of systemic levels has been demonstrated to not always adequately 
estimate relative dermal absorption rates, and in vivo microdialysis is currently the only 
technique to assess directly unbound drug levels in the dermis [67]. 
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4.3. MATERIALS AND METHODS 
 
4.3.1.  Materials 
Natrosol® 250 M (Aqualon, Hercules Inc., DE, USA), Flufenamic acid, 
modification II (Kali-Chemie Pharma, Hannover, D), Poly(D,L-lactide-co-glycolide) 
(50:50) with a molecular weight of 40000 to 75000 Da (Sigma Chemical Co., St. Louis, 
MO, USA), Polyvinyl alcohol (PVA) Mowiol® 4-88 (Kuraray Specialities Europe GmbH, 
Frankfurt, D), Soerensen phosphate buffer (pH 7.4), McIlvaine citric acid phosphate 
buffer (pH 2.2), Sodium hydroxide (all components from Merck, Darmstadt, D), 
Hypodermic stainless steel tubes type 304W, Stay-Clean soldering flux and  Super 
Solder Wire (Small Parts Inc. Miami Lakes, FL), Cuprophan® membrane (type RC 55 
8/200) of MWCO 10000 Da, approx. o.d. 200 µm, Loctite® Quick setTM Epoxy (Henkel 
Consumer Adhesives, Inc, Avon, OH), silica capilar tube with plastic cover (Polymicro 
Technologies Inc, Phoenix, AZ), Flo-texx® (Lerner Laboratories, Pittsburgh, PA), Veet 
depilatory cream (Reckitt Benckiser Inc., Berks, UK), Ketamin hydrochloride Ketamil® 
(Agrovet Ltda., Chile), chloral hydrate (Sigma- Aldrich Co., St. Louis, MO, USA), 
Introcan® 22G 1” (B. Braun Melsungen AG, Melsungen, D), Hematoxylin and Eosin Y 
(Sigma- Aldrich Co., St. Louis, MO, USA), Micro Test Tube 3810X (Eppendorf AG, 
Hamburg, D) 
4.3.2.  Equipment 
HPLC system: Autosampler LaChrom L-7200, Pump LaChrom L-7100, Diode 
array detector LaChrom L-7450, Interface D-7000 and Multi HPLC System Manager 
Software LaChrom D-7000 (Merck Hitachi, Japan); 74900-15 Infusion pump Cole Palmer 
Instrument Company (Vernon Hills, IL, USA); Probes for dermal microdialysis were 
manufactured and provided by Departmento de Farmacología, Facultad de Ciencias 
Biológicas, Universidad de Concepción – Chile. Leica TP1020 and Leica EG1150 H 
(Leica Microsystems GmbH, Wetzlar, D); Reichert-Jung microtome (Reichert-Jung, D) 
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4.3.3.  Microdialysis probes 
The probes were assembled using of cellulose tubing (12.000 MWCO) of 200 µm 
outer diameter and 10 µm wall thickness, sealed at one end with an epoxy plug. The 
open end was attached to the probe body composed by 26 Ga, 21 Ga and 30 Ga 
stainless steel hypodermic tubes as described in figure 25. A silica capillary tube with 
polyimide cover (150 µm o.d. and 75 µm i.d) was inserted into a stainless steel and 
cellulose tube. The efficient dialysis length was 30 mm. 
 
Figure 25: Diagram of concentric microdialysis probe. 
 
4.3.4.  Specimens 
Sprague-Dawley strain female rats, weighing 250–350 g, were obtained from the 
animal facility of Departmento de Farmacología, Facultad de Ciencias Biológicas, 
Universidad de Concepción – Chile. All the animal used were individually housed and 
maintained on a 12/12-h light–dark cycle at constant room temperature (22°C) with food 
and water ad libitum. 
All experiments were performed in accordance with the institutional guidelines 
and with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. 
The abdominal skin of the rats was prepared 18 h before the experiment under 
anesthesia. The abdominal hair was cut using a electrical machine. Subsequently, 
depilatory cream was applied (3 min) and gently washed off using cotton wipes and 
distilled water. The rat was returned to the animal facility overnight. 
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4.3.5.  Anaesthesia 
Previous to the microdialysis probe implantation, the animals were pre-
anesthetized using ketamine hydrochloride (100 mg/kg) administered intraperitoneally. 
After this the animals were anesthetized using chloral hydrate (300 mg/kg) administered 
intraperitoneally. This dose that was re-administered as required every 2 -3 h [101].  
 
4.3.6.  Probe implantation 
The microdialysis probes were implanted into the abdominal region of the rat 
under anaesthesia, as shown by the arrows in figure 26. The arrows indicate the flow 
direction of the perfusate. Dashed circles indicate the delimited application area of the 
formulation. 
 
Figure 26: Microdialysis probe implantation diagram and formulation application area in the 
rat abdominal region. 
 
4.3.7.  Retrodialysis probes recovery 
In vivo retrodialysis experiments were carried out using as perfusate solutions of 
2.5, 4 and 8 µg/ml flufenamic acid dissolved in Soerensen buffer pH 7.4. Ten samples 
were collected every 30 minutes (n = 8).  The percentage of relative recovery was 
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calculated using equation 4 (Chapter 1) . In all cases the relative recovery was > 90% 
and therefore in an acceptable range. 
 
4.3.8.  In vivo transdermal absorption experiments 
The non-buffered formulations (FFA HG, FFA NP HG and FFA HG + DF-NP), 
prepared as described in section 3.3.5 were used. 
The microdialysis probes have a perfusion flow of 1 µl/min. After the probe 
implantation, Teflon chambers (see figure 27) to delimit a circular application area of 15 
mm in diameter were stuck on the skin using a double side tape ring.  
 
Figure 27: Teflon chamber for in vivo applications. 
 
After 90 min (equilibrium time) the blank sample was collected. Subsequently, the 
Teflon piece was filled with approximately 1 ml of the corresponding formulation using a 
syringe, and samples of dialysate were collected every 30 min over a period of 6 hours 
after the formulation application. To avoid inter-individual differences, the three 
preparation were tested simultaneously in each rat. To exclude differences due to the 
application site, each formulation was alternated among the positions A, B and C for 
consecutive animals (see figure 26).  
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4.3.9.  Tape-stripping 
After 6 h of dialysate sample collection the animal was sacrificed and the skin 
from the application site, including the Teflon chamber and implanted section of the 
microdialysis probe, was removed and fixed over cork plates using pins. Subsequently, 
the Teflon chamber was take out from its place and the preparation wiped off from the 
surface using cotton swabs. A Teflon mask with a hole of 15 mm in diameter was placed 
over the application area. The tape stripping procedure and sample pooling was made as 
described in section 2.3.9. The remaining skin (15 mm in diameter) was punched out 
with the same diameter and collected in a separate flask. 
 
4.3.10.  Sample extraction and HPLC analysis 
The samples obtained from the tape stripping and deep skin layers were 
extracted by using 6 ml of 0.05 M NaOH, under stirring during 2 h at room temperature. 
One millilitre from this extract was transferred into Micro Test Tube (1.5 ml) and 
centrifugued at 12000 rpm for 1 min. The supernatant was analysed by HPLC using the 
method described in 2.3.11. 
 
4.3.11.  Histological sectioning 
This sample treatment was made under the standardized procedure at the 
Departamento de Anatomía Patológica (Universidad de Concepción). The skin samples 
were fixed in formalin (10% v/v) and afterwards treated using a Leica tissue processor 
using the following steps: 4 h in formalin, 1 h in ethanol 99% (3 times), 1 h in xylol (3 
times), and finally 1 h in paraffin at 60°C (2 times). After this process the tissue was 
transferred to a Leica embedding system where the tissue samples were embedded in a 
paraffin block (2 x 2 x 2 cm) to proceed with the histological transversal sectioning using 
a microtome.  The sections of the skin are placed in glass slides and dried on a forced air 
circulation oven at 60°C. The sections were stained as follows: the samples were 
In vivo flufenamic acid absorption using dermal microdialysis 
 
95
immersed 5 min in xylol (3 times), 1 min in ethanol 99%, 30 seconds in ethanol 70% and 
50% successively, and finally washed with water. Afterwards, the samples were 
immersed successively in a hematoxylin solution (1 - 5 min), in water (10 min), and eosin 
solution (30 sec – 2 min). The samples were passed through water, 30 seconds in 
alcohol 99% (6 times), and 30 seconds in xylol (3 times). After this process the samples 
were covered using a cover slide and sealed with Flo-texx®.  
 
 
4.4. RESULTS AND DISCUSSION 
 
4.4.1.  In vivo microdialysis 
In all experiments performed the dialysate samples analysed were under the 
detection limit (0.05 µg/ml) , n = 12 for each preparation. The high amount of hair follicles 
and close proximity of the capillary network to the probes [39] must be considered as  
important factors to explain the results obtained with the in vivo microdialysis 
experiments. The high clearance from the absorption site, considering that nanoparticles 
can also penetrate the hair follicle and act as on-site drug reservoir in deeper skin 
regions reduce the amount of drug able to reach the microdialysis probe, and therefore 
no drug could be detected in the dialysate. Another possible explanation of these results 
may be that flufenamic can bind in a high extent to plasma proteins [52], and it may bind 
also in a high extent to the proteins present in the epidermal and dermal environment 
(i.e. keratin, elastin, collagen), making the drug not available to be recovered in the 
dialysate.  
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4.4.2.  Microdialysis probe intradermal location 
Microscopic evaluation of the microdialysis probe location have shown the  
following distribution (Figure 28): 
 
Figure 28: Microdialysis probe intradermal location (n = 18) 
 
Its clear to see that most pf the probes were placed in the subcutaneous tissue 
and even in deeper tissue regions. However, to properly collect the drug permeated 
through the epidermis the optimal location would have been just beneath this layer. This 
non-optimal placement of the probe may explain the lack of drug detection in the 
dialysate due to tissue clearance, protein binding or enrichment of the highly lipophilic 
drug, flufenamic acid, in the subcutaneous fatty tissue.  
 
4.4.3.  Tape-stripping and deep skin layers 
The result obtained from the tape stripping and the deep skin layers are shown in 
figure 29. These results shown a high variability of the content of drug in the stratum 
corneum as well as in the deep skin layers.  
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Figure 29: Drug content per replicate found on stratum corneum and deep skin layers per 
replicate per formulation 
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One explanation for the stratum corneum may be that due to the presence of the 
microdialysis probe, the contact between the tape and the skin, even using the 2 kg 
weight, was not optimal and the removed stratum corneum layers were different in each 
tape application. In addition, the influence of the depilation cream could be not excluded. 
It can be speculated that in the deeper skin layer a strong binding to proteins and 
to the fatty tissue may occur. Moreover, a high clearance of the drug may occur in vivo  
due to the reach capillary network and the metabolic activity of the dermal tissue must be 
considered. Altogether, these different factors may influence the results and may be 
responsible for the high scattering of the data, making suitable conclusions impossible. 
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4.5. OVERVIEW 
There are many parameters that must be considered to optimize this in vivo 
microdialysis experimental work: 
1. Experiments performed between human and animal skin are difficult be 
representative from each other; 
2. Metabolic activity, clearance from the application site, and binding to 
different structures of the skin in vivo must be studied;  
3. A better placement of the microdialysis probe and study the different 
parameter which influence the drug recovery during the process are 
required. 
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CHAPTER 5: ADDITIONAL EXPERIMENTS 
 
 
 
 
 
Sections of this chapter have been published in the research article entitled 
“Nanoparticles - An efficient carrier for drug delivery into the hair follicles “ (Juergen 
Lademann, Heike Richter, Alexa Teichmann, Nina Otberg, Ulrike Blume-Peytavi, Javiana 
Luengo, Barbara Weiß, Ulrich F. Schaefer, Claus-Michael Lehr, Roger Wepf and 
Wolfram Sterry), European Journal of Pharmaceutics and Biopharmaceutics, 66 (2): 159-
164, 2007. 
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5.1. COLLABORATION WORK WITH OTHER RESEARCH GROUP 
 
The contribution to this work involved to establish a suitable semisolid preparation 
for nanoparticles and the preparation of the hydrogels containing sodium fluorescein or 
fluoresceinamine labelled PLGA nanoparticles. 
 
5.1.1.  Methods 
5.1.1.1 Preparation of the fluoresceinamine labelled nanoparticles 
containing hydrogel 
Biefly, a 1% suspension of fluorescein labeled nanoparticles (average diameter 
320 nm, PI 0.06) was prepared in water. A 3% hydroxyethylcellulose hydrogel (Natrosol® 
type 250 M pharma, Aqualon, Duesseldorf, D) was prepared separately. The polymer 
was dispersed in water under vigorous stirring (800 rpm) until it was homogeneously 
distributed; later on, the polymer was allowed to swell under low speed stirring (100 rpm) 
overnight. Both preparations were mixed at a proportion 1:1 and shaken until a 
homogeneous distribution of the particles in the gel was obtained, resulting in a 
nanoparticle content of 0.5% w/w. 
 
5.1.1.2  Preparation of sodium fluorescein containing hydrogel 
Briefly, a 0.003% sodium fluorescein-containing hydrogel (equivalent to the 
fluoresceinamine amount linked to the polymer) was prepared by dissolution of the dye in 
water and addition of the 1.5% hydroxyethylcellulose under stirring. Again, the 
preparation was stirred overnight at low speed (100 rpm) to allow swelling of the polymer. 
Both gels showed similar viscosities. 
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5.1.2.  Results 
The follicular penetration depth of the topically applied fluorescein in particle (A) 
and non-particle form (B), applied by massage of the skin, was determined by analyzing 
biopsies of porcine skin (Figure 30). Significant differences were observed: the particles 
penetrate much deeper into the hair follicles than the non-particle form if massage is 
applied. 
    
Figure 30: Examples of in vitro penetration of the dye-containing formulation into the hair 
follicles of porcine skin after application of a massage. (A) Dye in particle form. (B) Dye in 
non-particle form 14 
 
The same two formulations were gently applied to the skin without massage 
(Figure 31), resulting in penetration depth of the two formulations nearly identical. 
   
Figure 31: Examples of in vitro penetration of the dye-containing formulation into the hair 
follicles of porcine skin without massage. (A) Dye in particle form, (B) Dye in non-particle 
form 14. 
 
                                                 
 
14 Reprinted from European Journal of Pharmaceutics and Biopharmaceutics, 
doi:10.1016/j.ejpb.2006.10.019, Lademann J et al, Nanoparticles – An efficient carrier for drug delivery into 
the hair follicles, p4, Copyright 2006, with permission from Elsevier. 
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Penetration of particle-containing formulations was enhanced by mechanical 
massage, reaching significant deeper penetration depths than without massage. 
However, without any mechanical manipulation on the skin surface, no significant 
differences between the two formulations were observed. 
It may be expected that the small amounts of non-particle substances, with their 
relatively small size, penetrate better into the small hair follicles than the much larger 
particles. The results obtained show the opposite effect, but only in the case of a 
massage being applied. From the structure analysis of hair surface and hair follicles, it is 
known that the cuticle produced by keratinocyte desquamation forms a structured 
surface, which can be approximated by a zigzag relief [102]. This relief is determined by 
the thickness of the keratin cells, which is between 500 and 800 nm. If the hairs are 
moved by massage, the cuticle cells may act as a geared pump. Particles, comparable in 
size to the surface structure of the hairs and hair follicles, are probably pushed into the 
follicles by means of the pump movement of the hairs. These findings are in agreement 
with the results obtained by Toll et al. [41], the microparticles with a diameter of 750 nm 
penetrated better into the hair follicles of excised human skin than larger particles, when 
a massage had been applied. 
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5.2. INFLUENCE OF DIFFERENT PARAMETERS ON NANOPARTICLE 
PREPARATION 
 
5.2.1.  Variation of the polymer/quasi-emulsifier ratio  
Experiments were carrier out using the standard preparation method described in 
section 2.3.3. Additionally to the PLGA: PVA 6:2 ratio, also ratios of 6:1 and 6:4 were 
tested. 
Variations of the particle size of about 100 nm were obtained using different 
proportions of polymer and quasi emulsifier (see figure 32). Two different batches of 
each composition were prepared and measured three times each. Furthermore, it can be 
clearly seen that an increase in the PVA concentration results in a decrease in the 
particle size. Although the polydispersity index is influenced, the values lower than 0.1 
indicate a monodisperse size distribution. 
 
Figure 32: Effect of the ratio polymer/quasi-emulsifier used on the particle size 
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5.2.2.  Variation of the homogenization speed or time 
Changes on the homogenization speed using the same nanoparticles  
composition described in section 2.3.3 were tested. Instead of 13500 rpm, speeds of 
8500 and 20500 rpm were used while the homogenization time remain constant. 
Moreover, changes in the homogenization time using the formulation composition 
described in section 2.3.3 were tested. Instead of 10 min, 5 and 20 minutes were used. 
With an homogenization speed of 8500 rpm no nanoparticles could be obtained. 
No differences were observed with the further homogenization speed concerning the 
particle size. Only the polydispersity of the batches was altered, however the 
polydispersity index was in the same range indicating a monodisperse distribution 
(Figure 33). 
 
Figure 33: Effect of the homogenization speed on the particle size (homogenization time 10 
min) 
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Variations of the homogenization time between 5 and 20 minutes does not 
influence the particle size nor the polydispersity index. 
 
Figure 34: Effect of the homogenization time on the particle size (homogenization speed 
13500 rpm) 
 
In conclusion: The ratio PLGA:PVA does affect the particle size therefore this is 
crucial manufacturing parameter. However, if exceeding a critical homogenization speed 
and modifying the homogenization time do not seem to be crucial parameters. 
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5.3. NANOPARTICLE FREEZE-DRYING AND CRYOPROTECTION 
 
5.3.1.  Method 
Nanoparticles were prepared as described in section 2.3.3. Separately a 
saccharose [Saccharose (EU-Categorie)] saturated solution in water was prepared in a 
concentration of 64% w/w under vigorous stirring at room temperature. The amount of 
solution added was calculated according to the percentage in weight of saccharose per 
polymer weight present in the nanoparticles suspension. The amount of sugar used was 
in the range between 10 – 200 % related to the polymer content. One sample was 
collected from each concentration and the size measured by photon correlation 
spectroscopy. Afterwards, the nanoparticles were freeze-dried [Freeze-dryer Alpha 2-4 
LSC (Christ, Osterode, D)], re-suspended in water and the size of the particles 
measured. 
 
5.3.2.  Results 
A ratio 1:1 between polymer and saccharose was observed to be the lowest 
amount of cryoprotectant that produces no change on the particle diameter before and 
after the freeze drying process (see figure 35). 
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Figure 35: Effect of the cryoprotectant amount on particle size before and after freeze-drying 
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6.1. SUMMARY 
The skin, due to its structure, is considered a complex organ for drug 
delivery. Although composed by four main layers, only the stratum corneum is 
considered the most important barrier for the drug absorption through the skin.  
During the last years the transdermal drug delivery studies have been 
focused on overcoming the problems associated with the skin barrier properties. 
Following this objective, several physical and chemical enhancement methods have 
been studied to improve the drug transport through the skin, such as iontophoresis, 
electroporation, microneedles, chemical penetration enhancers, carriers as 
liposomes, solid lipid nanoparticles, among others.  
The use of polymeric nanoparticles has been extensively studied for peroral 
and parenteral applications however their use in the field of dermal application is rare 
and the mechanisms which affect skin absorption are almost unknown. Therefore, 
the interest of this research project was to study the potential of polymeric 
biodegradable nanocarriers on drug delivery to and through the skin. To prepare the 
nanoparticles, the well known biodegradable polymer PLGA 50:50 polymer was 
chosen, and to study the drug transport, flufenamic acid, an antiinflamatory, ionisable 
lipophilic drug was used. 
Using the solvent evaporation technique PLGA nanoparticles, with or without 
the incorporation of flufenamic acid, in the size range of 250 nm and a polydispersity 
index of less than 0.2 could be obtained. For these particles it has been shown, that, 
particularly for longer experimental times, PLGA nanoparticles improve the dermal 
drug permeation in vitro, using heat separated human epidermis in Franz diffusion 
cell systems. This result was confirmed by skin penetration studies with full-thickness 
human skin in the Saarbrücken model showing higher amounts of flufenamic acid in 
the viable epidermis and dermis when encapsulated flufenamic acid was applied. 
Moreover, for various incubation times constant concentrations in the stratum 
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corneum were found, indicating that the system has reached steady-state conditions. 
When permeation experiments were performed, the results have shown that 
enhancement effect is reached using loaded nanoparticles independent of particle 
size. Surprisingly the presence of drug-free nanoparticles in a preparation with 
flufenamic acid in solution has also increased the permeated amount of drug. 
Therefore the question arose which mechanistic effects are responsible for the 
enhancement effects of PLGA nanoparticles in combination with flufenamic acid. 
For the first time, it was demonstrated by confocal laser scanning microscopy 
and permeation experiments using buffered and non-buffered preparations that one 
of the mechanisms how PLGA nanoparticles increase the delivery of drug to the skin 
is due to an acidic nano-environment around the particles. This induces an 
increased concentration of the non-ionized form of the drug at the skin surface and 
therefore the concentration gradient between the stratum corneum surface and the 
dermal side of the epidermal membrane becomes steeped. Due to the local effect 
the total pH of the formulation is not affected.  
Other studies, developed in collaboration with Prof. Lademann’s research 
group, have shown that nanoparticles were able to penetrate into the hair follicles 
when massage was used. Such conditions must be considered for in vivo 
applications. 
In a preliminary in vivo study, using dermal microdialysis in rats, the effect of 
the nanoparticles could not be demonstrated due to methodological problems.  
The results presented in this thesis underscore the potential of polymeric 
biodegradable nanoparticles to be used as vehicles for transdermal drug delivery. 
Especially, the acidic pH of the nano-environment of the particles might be an 
advantage to develop special formulations designed for acidic drugs or might be 
used to re-establish the normal pH on the skin surface. 
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6.2. ZUSAMMENFASSUNG  
Auf Grund des strukturellen Aufbaus unserer Haut ist eine dermale 
Arneistoffinvasion als schwierig anzusehen. Obwohl die Haut aus vier 
verschiedenen Schichten aufgebaut ist, ist lediglich das Stratum corneum als 
Hauptbarriere für die Arzneistoffaufnahme durch die Haut anzusehen. 
Während der letzten Jahren wurden Studien zur transdermal 
Arzneistoffapplikation vor allem auf Problemstellungen fokussiert, die auf die 
Überwindung der Barriereeigenschaften der Haut ausgerichtet waren. So wurden 
verschiedene physikalische und chemische Methoden zur Erhöhung der 
Arzneistoffabsorption durch die Haut untersucht, wie zum Beispiel Iontophorese, 
Elektroporation, Microneedles, und chemische Penetrationsenhancer aber auch 
Trägersysteme wie Liposome und Solid Lipid Nanoparticles. 
Polymernanopartikel wurden sehr intensiv hinsichtlich ihrer Anwendung im 
peroralen und parenteralen Bereich untersucht. Zur dermalen Anwendung jedoch 
findet man für diese Präparate kaum Untersuchungen und der Mechanismus, wie 
die Hautabsorption beeinflußt wird, ist weitgehend unbekannt. Hieraus ergibt sich 
dann auch das Thema dieser Doktorarbeit in der das Potential bioabbaubarer 
Polymernanopartikel zur Erhöhung der dermalen Arzneistoffinvasion untersucht 
werden sollte. Zur Herstellung der Nanopartikel wurde das gut beschriebene 
Polymer PLGA 50:50 ausgewählt und Fufenaminsäure, eine antiinflamatorisch 
wirksame, ionisierbare, lipophile Substanz wurde benutzt um Effekte auf die dermale 
Arzneistoffinvasion aufzeigen zu können,. 
Durch Anwendung der sogenannten „Solvent-Evaporation-Technik“ konnten 
PLGA Nanopartikel sowohl mit als auch ohne Flufenaminsäure erhalten werden 
deren Partikelgröße bei etwa bei 250 nm lag und die einen Polydispersitätsindex 
unter 0.2 aufwiesen. Für diese Partikel konnte in Franz-Zellen Experimente mit 
humaner Epidermis gezeigt werden, daß vor allem bei längeren Anwendungszeiten 
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die Arzneistoffpermeation in vitro erhöht war. Dieses Ergebnis wurde durch 
Experimente mit humaner Vollhaut im Saarbrücker-Penetration-Modell bestätigt bei 
denen größere Mengen an Flufenaminsäure in der lebenden Epidermis und Dermis 
gefunden wurden, wenn Flufenaminsäure in der nanopartikulären Form eingesetzt 
wurde. Des weiteren wurden bei verschiedenen Versuchszeiten für das Stratum 
corneum konstante Flufenaminsäurekonzentrationen gefunden, die darauf 
hindeuten, daß sich ein sogenannter „steady state Zustand“ ausgebildet hat. Des 
weiteren konnte mittels Permeationsexperimente gezeigt werden, daß der 
penetrationsverstärkende Effekt unabhängig von der Partikelgröße durch mit 
Flufenaminsäure beladene Nanopartikel erreicht werden kann. Überrachenderweise 
führte jedoch die Anwesenheit von reinen PLGA-Nanopartikel in Präparationen, die 
Flufenaminsäure lediglich gelöst enthielten, ebenfalls zu einer erhöhten Permeation. 
Daher ergab sich die Frage welche Mechanismen für die penetrationsverstärkende 
Effekte von PLGA-Nanopartikel in Kombination mit Flufenaminsäure verantwortlich 
sind. 
Zum ersten Mal konnte mittels confokaler Laser Mikroskopie und 
Permeationsversuchen mit  gepufferten und nicht gepufferten Formulierung 
aufgezeigt werden, daß einer der Mechanismen, wie PLGA Nanopartikel die 
dermale Arzneistoffinvasion beeinflussen, durch das Ausbildend einer sauren 
Umgebung im Nanobereich um die Nanopartikel herum zu Stande kommt. Dies führt 
zu einer erhöhten Konzentration der undisoziierten Form des sauren Arzneistoffs an 
der Hautoberfläche was wiederum einen steileren Konzentrationsgradient zwischen 
der Oberfläche des Stratum corneum und der Grenzschicht Stratum corneum zu 
lebender Epidermis bedingt. Auf Grund des räumlich begrenzten Effektes wird der 
pH-Wert der Formulierung nicht beeinflußt.  
Weitere Versuche, die in Zusammenarbeit mit der Forschungsgruppe von 
Prof. J. Lademann, Charié Berlin, durchgeführt wurden haben gezeigt, daß 
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Nanopartikel bevorzugt dann in die Haarfollikel eindringen wenn sie mechanisch 
einmassiert werden. Dies entsprich durchaus den in vivo Anwendungsbedingungen. 
In einer ersten in vivo Studie, bei der das Verfahren der dermalen 
Mikrodialyse bei Ratten eingesetzt wurde, konnte auf Grund experimenteller 
Schwierigkeiten der Einfluß von  Nanopartikeln auf die dermale Invasion nicht 
aufgezeigt werden. 
Die Ergebnisse, die im Rahmen dieser Doktorarbeit ermittelt wurden, 
unterstreichen das Potential von biologisch abbaubaren Polymernanopartikel als 
Träger zur dermalen Arzneistoffinvasion. Besonders könnte der saure pH-Wert des 
Nanobereichs der Nanopartikel für saure Substanzen von Vorteil sein, um hier 
spezielle Formulierungen zu entwickeln, oder dieses Phänomen könnte dazu 
ausgenutzt werden den normalen leicht sauren pH-Wert auf der Hautoberfläche 
wieder herzustellen. 
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